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The present PhD project belongs to the general theme of scientific 
investigation relative to the study of biological functions of Annexin A1 both in 
physiological and in pathological processes. The aim of this work has been to 
identify and characterize in details the biological mechanisms underlying the 
protein involvement in tumor progression, with particular attention to 
pancreatic cancer. Few scientific works have reported information about the 
correlation of Annexin A1 with pancreatic cancer progression. The study of 
patients’ biopsies had shown that protein expression was associated to the 
increase of metastatization degree, a minor cell differentiation and a minor 
time of survival of patients. To better define the role of Annexin A1 in this 
model, we analyzed four cell lines of human pancreatic cancer: MIA PaCa-2, 
PANC-1, BxPC-3 and CAPAN-2. All of them presented very similar levels of 
Annexin A1 expression but only MIA PaCa-2 and PANC-1 showed a 
mesenchymal phenotype, as demonstrated by the high levels of vimentin, a 
typical mesenchymal marker, so only these ones are described as more 
aggressive cells. For this reason, we continued the investigation of Annexin 
A1 in MIA PaCa-2 and PANC-1 cells. By immunofluorescence assay we 
showed that Annexin A1 co-localized with Focal Adhesion Kinases and F-
actin, two proteins typically involved in cell migration, so we postulated the 
hypothesis that Annexin A1 could be involved in cell motility. To identify the 
functional role of Annexin A1 in these cell lines, a down-modulation of protein 
expression was performed by transient transfection of specific siRNAs. 
Through the assays of Wound healing and invasion through a coating of 
matrigel, we showed that MIA PaCa-2 and PANC-1 with lower Annexin A1 
levels migrated and invaded slower than control cells.  
Several functions of Annexin A1 are carried out by its extracellular 
form which interacts with the Formyl Peptide Receptors (FPR) in both 
autocrine and paracrine manner. The expression of the receptor isoforms 
FPR-1 and FPR-2 was analyzed by cytofluorimetric assay and PCR. Receptor 
activation was studied in presence of either agonists such as fMLP and Ac2-
26, a mimetic peptide of Annexin A1, or antagonists like Boc-1. To verify if the 
pathways triggered by the activation of Formyl Peptide Receptors were 
involved in the processes of cell migration and invasion, we performed the 
assays of Woung healing and invasion with MIA PaCa-2 and PANC-1 in 
presence of receptor agonists and antagonists: fMLP and Ac2-26 stimulated 
migration and invasion in either cell line, while antagonist Boc-1 reverted this 
effect. Through compartimentalized protein extractions, MIA PaCa-2 cell line, 
but not PANC-1 cells showed, in addition to the full length form of 37kDa, a 
shorter form of 33kDa relative to the C-terminal portion, the likely result of a 
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Moreover only MIA PaCa-2 externalized Annexin A1 in the 37, 33 and 
3kDa forms; this last one corresponded to the N-terminal portion which is 
considered as the sequence with the main biological functions. So we focused 
our attention on the extracellular form of Annexin A1: following the 
administration of a specific blocking antibody, MIA PaCa-2 cells lost their 
capability of migration and invasion. On the other hand, PANC-1 were not 
affected by the antibody, confirming the absence of the protein in their 
supernatant. Furthermore, after the addition of the supernatant of MIA PaCa-
2, the PANC-1 cell line acquired a greater migration rate, confirming the 
importance of the protein in the processes of migration and invasion. 
To better characterize the role of Annexin A1 in vitro and, above all, in 
vivo, we generated Annexin A1 knock-out clones of MIA PaCa-2 cells. We 
chose the technique of Gene-CRISPR/Cas9 with which we created the 
genomic delection of Annexin A1, compared with wild type cells and cells 
transfected with PGS, a scrambled vector used as technical control. By the 
proteomic analysis of the obtained clones, 36 proteins appeared up-regulated 
and 26 down-modulated in absence of Annexin A1, these proteins could be 
involved in several cell pathways like cell proliferation and trafficking, 
metabolism, cytoskeletal organization and others. Based on the previous 
data, we preferred to better characterize the aspect of the cytoskeletal 
organization. We confirmed the variation of some proteins that seemed 
particularly interesting: for example we validated the down-modulation of 
vimentin and lamin A/C; on the other hand up-regulation of CD44 and 
cytokeratin 18 was observed. By immunofluorescence analysis, a strong 
depolimerization of F-actin in MIA PaCa-2 knock-out for Annexin A1 was 
detected. So we analyzed the processes of migration and invasion showing 
that MIA PaCa-2 without Annexin A1 migrated and invaded in a significant 
slower manner compared with MIA PaCa-2 wild type and transfected with 
PGS. Furthermore, no modifications were observed in the expression of 
proteins involved in the pathways triggered by Formyl Peptide Receptors. In 
fact MIA PaCa-2 knock-out for Annexin A1 showed very similar levels of the 
receptor isoforms 1 and 2. These receptors appeared active since the 
migration and invasion rate of the MIA PaCa-2 cells knock-out for Annexin A1 
increased in the presence of agonist Ac2-26 and decreased with antagonist 
Boc-1. Moreover, to complete the characterization of clones, we analyzed the 
cell proliferation, showing that these cells proliferated more rapidly, had higher 
S/G2 phases and higher levels of proteins as Cyclin A1, phospho-ERK and 
ALDH7A1.  
Finally, MIA PaCa-2 wild type, PGS and Annexin A1 knock-out have 
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mice. In the absence of Annexin A1, the tumor mass appeared not affected 
and retained a volume very similar to the tumor generated by MIA PaCa-2 
wild type and PGS but the metastatization degree strongly decreased. This 
phenomenon was analyzed in mice livers which represent the first organ 
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Annexin 1 (ANXA1) is a multifunctional protein of 37 kDa, and 
represents the first characterized member of the annexin superfamily, so 
called since their main property is to bind (i.e. to annex) cell membranes in 
Ca2+-dependent manner. ANXA1 is over-expressed in tissues from patients 
affected by pancreatic carcinoma (PC), where the protein seems to be 
associated with the malignant transformation and the poor prognosis. In this 
PhD project, experiments were performed to understand the role of ANXA1 in 
human PC development with particular attention to migration and invasion 
processes. We observed in all the analyzed PC cell lines, a huge expression 
and a localization of ANXA1 mostly on the motility sub-structures. 
Interestingly, in MIA PaCa-2 cells we found also two cleaved forms of ANXA1 
(33 and 3 kDa) that localize at cellular membranes and are secreted outside 
the cells, as confirmed by MS analysis. MIA PaCa-2 and PANC-1 cell lines 
express Formyl Peptide Receptors (FPRs) 1 and 2: the treatment of this cells 
with the ANXA1 mimetic peptide, Ac2-26, induced intracellular calcium 
release, consistent with nFPR activation, and significantly increased cell 
migration/invasion rate. ANXA1 effects on MIA PaCa-2 and PANC-1 migration 
and invasiveness were observed both by down-modulating its expression 
through siRNAs and by treatment with a blocking antibody. The importance of 
the secreted form of ANXA1 in cellular motility was confirmed when MIA 
PaCa-2 were compared with PANC-1 cells that lack both the cleaved and the 
externalized forms. Moreover, the treatment of PANC-1 cells with MIA PaCa-2 
supernatants, significantly increased the migration rate of these cells. To 
better characterize the functional role of the protein in PC progression, 
ANXA1 Knock-Out (KO) clones from MIA PaCa-2 cells were obtained. The 
expression of several proteins was affected by the absence of ANXA1, 
particularly the cytoskeletal organization was negatively conditioned. In fact, 
MIA PaCa-2 ANXA1 KO lost their migratory and invasive capabilities, 
proliferated more rapidly and seemed to acquire a less aggressive phenotype. 
To confirm this aspect the MIA PaCa-2 wild type, PGS (the scrambled vector) 
and ANXA1 KO were implanted to create orthotopic xenograft in vivo. The PC 
mass of ANXA1 KO MIA PaCa-2 was not significantly smaller than the other 
experimental points, but the metastatization degree appeared particularly 
reduced as showed on livers of mice with MIA PaCa-2 wild type and PGS 
which showed a higher degree of metastatic lesions compared to MIA PaCa-2 
ANXA1 KO.  
This project provides new insights on the role of ANXA1 in PC 
progression. In in vitro models, the intracellular ANXA1 is involved in the 
maintenance of the cytoskeleton integrity. When secreted, the protein 




- 5 - 
 
confirmed by in vivo xenograft experiments where ANXA1 appears to 
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1.1  Pancreatic anatomy 
The pancreas is a soft, elongated, flattened gland of 12-20 cm in 
length and a weight of about 100 grams. The name pancreas derives from the 
Greek roots ‘pan’ meaning ‘all’ and ‘creas’ meaning ‘flesh’ [1]. It is composed 
by four parts as head, neck, body and tail in a manner represented in figure 




Figure 1.1: Pancreas sections [2] 
 
The tail of the pancreas and the spleen are in the left upper quadrant 
of the abdomen, instead the head of the pancreas is in the right upper 
quadrant just to the right of the midline (Fig. 1.2):  
 
 The head of the pancreas lies in the loop of the duodenum; 
 The tail of the pancreas lies near the hilum of the spleen; 
 The body of the pancreas lies posterior to the distal portion of the 
stomach between the tail and the neck; 
 The portion of the pancreas that lies anterior to the aorta is thinner 
than the adjacent portions of the head and body of the pancreas. This 
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region is sometimes designated as the neck of the pancreas and 
marks the junction of the head and body; 
 The close proximity of the neck of the pancreas to major blood vessels 
posteriorly including the superior mesenteric artery, superior 
mesenteric-portal vein, inferior vena cava, and aorta limits the option 
for a wide surgical margin when pancreatectomy is done; 
 The common bile duct passes through the head of the pancreas to join 
the main duct of the gland near the duodenum. The portion nearest 
the liver lies in a groove on the dorsal aspect of the head; 
 The minor papilla where the accessory pancreatic duct drains into the 
duodenum and the major papilla (ampulla of Vater) where the main 




Figure 1.2: Anatomic relationships of the pancreas with surrounding organs and 
structures 
 
The celiac trunk and the superior mesenteric artery both arise from the 
abdominal aorta and have multiple branches that supply several organs 
including the pancreas. The anastomosis of their branches around the 
pancreas provides collateral circulation that generally assures a secure 
arterial supply to the organ. Most of the arteries are accompanied by veins 
that drain into the portal and splenic veins as they pass behind the pancreas. 
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The superior mesenteric vein becomes the portal vein when it joins the 
splenic vein [3]. 
 
 
1.1.2 The exocrine portion 
The exocrine cells are packed with membrane-bound secretory 
granules which contain digestive enzymes that are exocytosed into the lumen 
of the acinus. The pancreatic acini are arranged in clusters like grapes at the 
ends of a branching duct system. Centroacinar cells are typically located at 
the junction of an acinus or acinar tubule with a small ductule, but they may 
be interspersed within an acinar tubule.  
 
 
Figure 1.3: Pancreatic tissue with acinar, centroacinar and ductal cells [5] 
 
The acinar cells have several short, slender microvilli about 0.2 µm in 
length and extend into the lumen of the acinus. The lumen typically contains 
flocculent electron-dense material, which is the secreted digestive enzymes. 
Thin filaments form the axis of the microvilli as well as a network beneath the 
apical plasmalemma. These microfilaments apparently play a structural role 
because their disruption causes expansion of the acinar lumen and loss of 
microvilli. In figure 1.3 are shown the acinar cells which are larger than 
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centroacinar cells and are easily identified because of the darkly stained the 
zymogen granules (ZG). The basal portion (B), in the opposite site of the 
luminal one (A), of the canard cells lies next to the interstitial space that 
contains vessels (V), nerves and connective tissue. Nuclei (N) with nucleoli 
(n) are in the basal portion of the acinar cells: the nucleus usually is spherical, 
about 6 µm in diameter, with one or more nucleoli in the interior. Mitochondria 
(m) appear elongate, cylindrical structures that may appear oval in cross-
section and may contain well-developed cristae and many matrix granules 
and they occur throughout the cytoplasm, among the granular endoplasmic 
reticulum or zymogen granules and adjacent to the basolateral cell border. 
The cytoplasmic matrix occupies about 45% of the cell volume. Tight 
junctions form a belt-like band around the apical end of the cell and are 
produced by the apposition of the external membrane leaflets of neighboring 
cells. These junctions prevent the reflux of secreted substances from the duct 
into the intercellular space. Gap junctions are distributed on the lateral cellular 
membranes and are formed by the apposition of larger, disk-shaped 
membrane plaques, they allow communication between cells. Rough 
endoplasmic reticulum (RER) occupies about 20% of the cell volume and fills 
most of the basal region of the acinar cells, although small amounts also 
occur in the apical region adjacent to and among the zymogen granules. This 
reticulum is composed of numerous parallel cisternal membranes covered 
with closely spaced attached ribosomes, giving the structures a granular 
appearance. The Golgi complex (G) is located between the nucleus and the 
mass of zymogen granules present in the resting gland, it consists of 
flattened, membranous saccules as well as small vesicles or vacuoles that 
contain flocculent electron-dense material. The Golgi complex is believed to 
play an important role in the transport of secretory proteins and the formation 
of zymogen granules, in fact the precursors of zymogen granules that formed 
starting from Golgi complex are membrane-bound vesicles slightly larger than 
zymogen granules and much less numerous, occupying only about 2% of the 
cytoplasm. Studies of the chemical composition of the zymogen granules, that 
appear as spherical, membrane-bound vesicles and slightly less than 1 mm in 
diameter, have shown that they contain about 12 to 15 different digestive 
enzymes, which make up about 90% of the granule protein. [6; 7].  
About the ductal system, the duct of Wirsung is the main pancreatic 
one from which originates the accessory duct of Santorini, other connections 
are the interlobular ducts, that drain into the main duct throughout the 
pancreas and the intralobular ducts (sometimes called intercalated ductules) 
that link acinar tubules to the interlobular ducts. Enzymes from acinar cells 
are released into a bicarbonate-rich solution that is secreted by the 
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centroacinar and ductal cells and flows from the acini and acinar tubules to 
the intralobular ducts, then into the interlobular ducts and main duct and, 
finally, into the duodenum at the major or minor papillae. The integrity of the 
duct system is of key importance in preventing entry of the exocrine enzymes 
into the interstitial space where they may be activated and cause tissue 
damage manifest as pancreatitis. The main and interlobular ducts have thick 
dense collagenous walls. The connective tissue component of the duct wall 
becomes progressively thinner as the ducts branch and become narrower. 
Intercellular tight junctions, also called zonula occludens, between duct cells, 
centroacinar cells and acinar cells play a major role in preventing leakage of 
the duct system [6]. 
Ductal cells express markers such as cytokeratin 19 (K19), cystic 
fibrosis transmembrane receptor (CFTR), carbonic anhydrase II (CAII), DBA 
lectin and transcriptional factors as HNF1β (Hepatocyte Nuclear Factor 1 β), 
HNF6 (Hepatocyte Nuclear Factor) and Sox9 [8]. 
1.1.3 The endocrine portion 
The bulk of the pancreas is composed of pancreatic exocrine cells and 
their associated ducts, but embedded within this exocrine tissue, there is 
roughly one million small clusters of cells called the Islets of Langerhans, 
which are the endocrine cells of the pancreas and secrete insulin, glucagon 
and several other hormones. Islets vary greatly in size, ~70% are in the size 
range of 50-250 μm in diameter in humans with an average in the range of 
100-150 μm [9]. Smaller islets are dispersed throughout the acinar lobules 
and most larger islets lie along the main and interlobular ducts of the 
pancreas. Most islets are spherical or ellipsoid, but they can be irregular in 
shape, reflecting sometimes the pressure of an adjacent structure, often a 
duct. In the tail of the pancreas there is a higher population density of islets 
than in the head and body [10; 11; 12; 13]. In adult humans the number of 
islets is calculated to be 500000-1 million whereas, they comprise 1-2% of the 
pancreas in adults of most mammalian species. In addition to the islets, 
isolated islet cells may be found dispersed in the acinar lobules or in 
association with ducts [14; 15]. The differences among the islets are 
detectable through electron microscopy (Fig.1.4). 
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Figure 1.4: The α-, β-, and δ-cells are labeled. At the ultrastructural level, the cell 
types are distinguished primarily by differences in their granules. The α-cell granules 
are typically slightly larger than β-cell granules. δ-cell granules are typically less 
densely stained than the granules in α- and β-cells. Scale bar = 4 μm [5] 
 
Each islet is surrounded and penetrated by a rich network of 
capillaries lined by a fenestrated endothelium, these capillaries are arranged 
in a portal system that conveys blood from the islets to acinar cells. This 
insula-acinar portal system consists of afferent arterioles that enter the islet, 
form a capillary glomerulus and leave the islet as efferent capillaries passing 
into the exocrine tissue. A parallel arterial system supplies blood directly to 
the exocrine pancreas and permits the local action of islet hormones on the 
exocrine pancreas. Acinar cells surrounding islets of Langerhans, termed 
peri-insular acini, are morphologically and biochemically different from acini 
situated farther away (tele-insular acini): they appear as have larger cells, with 
different ratios of specific digestive enzymes [16]. β cells, the most numerous 
(50% to 80%), secrete insulin, α cells (5% to 20%) secrete glucagon, PP cells 
(10% to 35%) secrete pancreatic polypeptide, δ cells (5%) secrete 
somatostatin. Other rare cell types, like ε ones, occur in the islets. In humans, 
the islets are subdivided into units, each of which exhibits a central 
aggregation of β cells surrounded by varying numbers of peripherally located 
cells that secrete the other hormones (Fig.1.5). 
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Figure 1.5: a. Gross anatomy of the pancreas; b. The exocrine pancreas; c. a single 
acinus; d. A pancreatic islet embedded in exocrine tissue [17]. 
 
1.2 Pancreatic development 
The pancreas appears as a complex organ comprised of three critical 
cell lineages: islet, acinar and ductal. As is the case for other endodermal 
organs, the development of the pancreas is thought to result from interactions 
between the epithelium and its associated mesenchyme. The pancreas is first 
discernible as the dorsal bud that emerges from the proximal duodenum at 
four weeks of gestation. Particularly, the pancreatobiliary system appears at 
gestation week 5 in the human; then the fusion of the dorsal and ventral 
anlagen occurs during week 7. Full development of acinar tissue extends into 
the postnatal period. In mice, pancreatic development begins at embryonic 
day 8.5 (e8.5) and is largely complete by day e14.5 [18; 19]. Its embryological 
origin has two buds developing on the dorsal and the ventral side of the 
duodenum. Pancreatic development is a tightly regulated process, with the 
endocrine and exocrine compartments emerging from a common progenitor 
population; this process involves the interplay of Hedgehog and Notch 
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signaling and other cues from the mesenchyme. Notably, Pdx1 is required for 
the specification of pancreatic lineages [20]. 
The pancreas develops from two outgrowths of the distal part to the 
stomach. The ventral diverticulum gives rise to the common bile duct, 
gallbladder, liver and the ventral pancreatic portion that becomes a part of the 
head of the pancreas with its duct system including the uncinate portion of 
this organ. The dorsal pancreatic anlagen gives rise to a portion of the head, 
the body and tail of the pancreas including a major duct that is continuous 
through the three regions. Fusion of the duct systems results in the formation 
of the main pancreatic duct from the ducts of both dorsal and ventral anlagen. 
The caudal portion of the head of the pancreas (uncinate) and the major 
papilla (ampulla of Vater) are derived from the ventral anlagen. It becomes 
apparent that the duct of Santorini is derived from the dorsal part, whereas 
the duct of Wirsung is derived from the fusion of duct systems of both dorsal 
and ventral anlagen and drains into the duodenum at the ampulla of Vater. 
Furthermore, “common channel” refers to the fused portion of the bile and 
pancreatic ducts proximal to entry into the duodenum. The common channel 
has received much attention because stones in the biliary tract (gallstones) 
may lodge in the common channel causing obstruction of both pancreatic and 
biliary duct systems which is frequently the cause of acute pancreatitis [21]. 
Of intense interest in the study of ductal cells has been their potential 
capacity to give rise to islet cells, following the model reported in figure 1.6. If 
possible, this would be another vehicle to generate islet cells for 
transplantation as well as a potential treatment of diabetes mellitus, 
furthermore One study concluded that β cell progenitors can be activated in 
the injured adult mouse pancreas and are located in the ductal lining [22; 23]. 
Generally, metaplasia is the word used to define the conversion or 
replacement of one differentiated cell type with another in the context of a 
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Figure 1.6: Mature duct cells regress to a less differentiated phenotype and then act 
as pancreatic progenitors to form new acini, islets and ducts [24]. 
 
1.3 Pancreatic functions 
1.3.1 The exocrine portion 
The pancreas can be considered as two glands that are intimately 
mixed together into one organ. The exocrine portion of the pancreas plays a 
major role in the digestion of food. The stomach slowly releases partially 
digested food into the duodenum as a thick and acidic liquid called chyme. 
The acini, the major functional units of the pancreas, secrete pancreatic juice 
to complete the digestion of chyme in the duodenum. They respond to several 
intracellular messengers as acetylcholine (Ach), cholecytokinin (CCK), 
bombesin (GRP –gastric releasing peptide-) and substance P. Pancreatic 
juice is a mixture of water, salts, bicarbonate and many different digestive 
enzymes. The pancreatic enzymes are specialize in digesting specific 
compounds found in chime and it is possible to recognize:  
 Pancreatic amylase: it breaks large polysaccharides like starches and 
glycogen into smaller sugars such as maltose, maltotriose and 
glucose. Maltase, secreted by the small intestine, then breaks maltose 
into the monosaccharide glucose, which the intestines can directly 
absorb. 
 Trypsin, chymotrypsin (endopeptidases) and carboxypeptidase 
(esopeptidase): they are protein-digesting enzymes that break 
proteins down into their aminoacid subunits. These aminoacids can 
then be absorbed by the intestines. 
 Pancreatic lipase: it is a lipid-digesting enzyme that breaks large 
triglyceride molecules into fatty acids and monoglycerides. Bile 
released by the gallbladder emulsifies fats to increase the surface 
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area of triglycerides that pancreatic lipase can react with. The fatty 
acids and monoglycerides produced by pancreatic lipase can be 
absorbed by the intestines. 
 Ribonuclease and deoxyribonuclease: they digest nucleic acids. 
Ribonuclease breaks down molecules of RNA into the sugar ribose 
and the nitrogenous bases adenine, cytosine, guanine and uracil. 
Deoxyribonuclease digests DNA molecules into the sugar deoxyribose 
and the nitrogenous bases adenine, cytosine, guanine, and thymine. 
The mechanism by which proteins are exported is well characterized: 
they are first synthesized on polysomes, later they cross the RER (thanks to 
the SRP –signal-peptide recognition particle– a cytosolic protein which 
facilitates the binding of mRNA-ribosomal complex to RER) and the Golgi 
apparatus. Starting from this one, the secretory granules then move by an 
undefined mechanism to the apical portion of the acinar cells, fuse with it and 
discharge their contents into the luminal space by an exocytosis process. 
If these proteins are secreted inside the pancreatic parenchyma, the 
consequences can be potentially disastrous with a strong autodigestion. For 
this reason the enzymes are produced like proenzymes and are packaged in 
the zymogen granules. They remain inactive until their reach to the duodenal 
lumen. For example, once in the duodenum, trypsinogen, the major 
proteolytic enzyme is converted to active trypsin by an enzyme called 
enterokinase, a brush border enzyme expressed in the duodenal mucosa. 
The same active trypsin is essential for the activation of other proteolytic and 
lipolytic pancreatic enzymes. Finally, acinar cells product also the trypsin 
inhibitor, which is packaged in zymogen granules together with trypsinogen 
and activates small amounts of trypsin that may form inside the cells or the 
body of pancreas [25; 26].  
The basal volume of pancreatic secretion is estimated to be 0.2/0.3 
ml/min, although, when stimulated, pancreatic secretion clan reach 4.0/4.5 
ml/min; compressively, the daily output of pancreatic juice is approximatively 
of 2.5 L [27]. 
Duct cells secrete a bicarbonate-rich fluid at a considerable variable 
flow rate of 0.4 ml/min depending of the state of pancreas stimulation. The 
purpose of alkaline secretion is to neutralize gastric acid that enters the 
duodenum, an essential process for achieving optimal conditions for 
pancreatic enzyme activity. In fact, inadequate bicarbonate secretion with 
failure to reach a neutral pH, as occurs in chronic pancreatitis, contributes to 
severe maldigestions. As it is elucidated in figure 1.7, carbonic anhydrase 
catalyzes the production of HCO3
- and H+ from carbonic acid. HCO3
- is then 
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transported across the luminal plasma membrane by a HCO3
-/Cl- exchanger. 
The major source of luminal Cl- is now believed to be from the concomitant 
secretion of the anion via a luminal membrane Cl- channel. This channel is 
regulated by cAMP-dependent protein kinase or CFTR protein, which is 
defective just in cystic fibrosis. The recycling of Cl- is, therefore, a major factor 
in determining HCO3
- secretion: the inhibition of Cl- channel activity will 
decrease HCO3
- secretion. This may explain why pancreatic insufficiency 
develops in some cystic fibrosis patients, as it results from defective ductal 
secretion. In this condition, proteinaceous acinar secretions become 
concentrated and their precipitation can cause blockage and destruction of 
pancreatic ducts. Proton generated during the production of HCO3
- must be 
rapidly transported out of the cells or cell pH would drop precipitously. This 
occurs at the basolateral membrane through two different mechanisms. One 
involves Na+/K+ ATPase (proton pump), different from the one found in 
parietal cells of the stomach, in the basolateral membrane and may provide 
an alternative and perhaps primary mechanism for rapid proton extrusion. 
Na+/K+ ATPase is also present in the basolateral membrane, it is necessary 
for producing favorable electrochemical gradients for Cl- secretion. Na+, some 
K+ and water accompany HCO3
- secretion, mostly entering the duct lumen by 
passive paracellular diffusion, their rate of transport is determined by 




Figure 1.7: Mechanism of active bicarbonate secretion by pancreatic ductal cells 
[27]. 
 
Therefore, ductal cells of the pancreas have recently been under 
scrutiny as they may be pancreatic stem cells. When the pancreas is 
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damaged by duct ligation, cellophane wrapping, pancreatectomy, genetically 
targeted destruction by IFNγ or when cells are specifically destroyed by 
streptozotocin, there is some increase in the mitotic activity in the ducts and 
limited regeneration of the organ. This led to the hypothesis that, during 
regeneration, duct cells act as progenitors for the generation of new 
pancreatic cells, however, only cell tracing experiments would make the link 
between the cells observed in the ducts and new islets [28].  
 
 
1.3.2 The endocrine portion 
The endocrine portion of the pancreas controls the homeostasis of 
glucose in the bloodstream. In general, the islet is composed of 5 cell types: 
α, β, δ, ε, and PP that produce glucagon, insulin, somatostatin, ghrelin and 
pancreatic polypeptide, respectively. Of these hormones, insulin is the 
primary hormone whose actions on a variety of cell types shifts, on balance, 
the metabolic flux of nutrients (primarily glucose) toward storage forms of 
energy (glycogen, protein and fat) and is therefore considered an anabolic 
hormone. By contrast, glucagon, acting typically in an antagonistic fashion to 
insulin, functions as a catabolic hormone, causing breakdown of glycogen, 
protein and fat. The other hormones of the islet appear to have either a 
secondary or uncertain physiologic role in metabolism: somatostatin functions 
in the inhibition of insulin and glucagon secretion, whereas the significance of 
pancreatic polypeptide and ghrelin are unclear [29; 30].  
Nutrients in the form of glucose, aminoacids and long chain-free fatty 
acids (LC-FFAs) are absorbed from the gastrointestinal tract into the portal 
circulation, where they are detected by β cells via an integrated biochemical-
based sensing mechanism (in the case of aminoacids, the β cell primarily 
responds to valine and arginine). This sensing mechanism is tightly coupled 
to the production and release of insulin into the blood stream.  
Two phases of insulin release are observed: an acute or first phase 
and a more chronic or second one. First, insulin release is reflective of 
membrane-docked of insulin granules that are engaged immediately upon 
stimulus coupling. In the second phase, insulin release represents pre-formed 
or newly-formed granules recruited to the membrane after the immediate 
stimulus response. Studies have shown that a positive autocrine/paracrine 
response of insulin (via its receptor signaling) is important in the maintenance 
of insulin synthesis in the β cell; the secretion mechanism is described in 
figure 1.8.  
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Figure 1.8: The insulin secretion mechanism in detail [31]. 
 
Although the insulin receptor is present in a host of key metabolically 
active organs (for example, liver, muscle, fat and brain) and cells (α cells and 
β cells of the pancreatic islet). Its actions in each of these organs and cells 
differ: in the liver, insulin promotes glycolysis, inhibits gluconeogenesis, 
promotes synthesis of glycogen (glycogenesis) and inhibits the breakdown of 
glycogen (glycogenolysis); in adipose tissue, insulin promotes glucose uptake 
and glycolysis, the synthesis and storage of triglycerides (TGs) and the 
inhibition of lipid breakdown; in skeletal muscle, insulin promotes glucose 
uptake and glycolysis, the synthesis and storage protein and the inhibition of 
protein breakdown; in bone, finally, insulin acts primarily on osteoblasts to 
promote osteoclast activity and enhance production and release of 
osteocalcin (OCN), a hormone that supports insulin release by the β cell. 
Insulin actions in the brain are now better appreciated and include the 
regulation of female fertility, appetite, and overall glucose homeostasis. Within 
the β cell, paracrine/autocrine effects of insulin sustain β cell growth, survival 
and function. Taken together, the actions of insulin in these tissues support 
anabolic pathways that lead to the generation of ATP and the conversion of 
ingested nutrients into the major storage forms of energy (glycogen, protein 
and fat) [30].  
In contrast, α cells of the pancreatic islets secrete the hormone 
glucagon, which serves to counterbalance the actions of insulin. Glucagon 
promotes glycogenolysis and inhibits glycogenesis in liver and skeletal 
muscle, enhances lipolysis and inhibits triglyceride synthesis in adipose 
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tissue. α cells also express cell surface insulin receptor and respond locally to 
secreted insulin by suppressing glucagon release.  
The liver is thought to secrete an yet unidentified factor(s) that appears 
to feed back to support β cell mass. The gut secretes incretin hormones 
(glucagon-like peptide-1 or GLP-1 and glucose-dependent insulinotropic 
peptide or GIP), which support glucose-dependent insulin secretion and β cell 
replication. Both GLP-1 and GIP are proteolytic products of the larger pro-
glucagon peptide, which is also produced by α cells of the islet. However, it is 
unclear whether α cell-derived incretins are a major contributor to β cell 
function/replication, although at least one study using human tissue has 
suggested that it may contribute. 
In addition, a healthy gut microbiota profile is thought to be essential to 
maintain leanness and normal β cell function. Furthermore, the cells of the 
central nervous system are known to secrete multiple peptides (melanin 
concentrating hormone –MCH-, serotonin and prolactin –PRL- and others) 
that have been shown both in vitro and in vivo to support β cell function and 
proliferation. Likewise, bone-derived OCN has been shown to support β cell 
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2.1 Introduction: epidemiology, etiology and symptoms  
Pancreatic cancer (PC) is the fourth leading cause of cancer death in 
the West World countries. It accounts for 277.000 new cases diagnosed each 
year in the world, among which approximately 49.000 occur in the USA and 
Europe [34]. With a 5-year survival rate of only 3% and a median survival of 
less than 6 months, a diagnosis of PC represents now the true problem for 
this tumor. Due to a lack of specific symptoms and limitations in diagnostic 
methods, the disease often eludes detection during its formative stages. 
Whipple and colleagues reported the first pancreaticoduodenectomy in 1935 
and surgery since offers the only possibility of cure, although surgical 
intervention alone rarely achieves a curative end point but, for the 15/20% of 
patients who undergo potentially curative resection, the 5-year survival is only 
20% [35; 36]. 
The etiology of PC remains poorly defined, although important clues of 
disease pathogenesis have emerged from epidemiological and genetic 
studies. PC is generally associated with advancing age: rare before the age of 
40, it gradually culminates in a 40-fold increased risk by the age of 80. The 
incidence of PC is declining slowly in white men, but it is increasing in other 
groups, possibly because of changes in smoking patterns. Women account 
for 57% of new cases. Smoking, diabetes and obesity increase risk, instead a 
link between alcohol or coffee consumption and PC has not been verified [37; 
38; 39; 40]. Physical activity, high fruit and vegetable intake and, possibly, 
nonsteroidal anti-inflammatory drugs reduce the risk [41]. On the genetic 
level, numerous studies have documented an increased risk (approximately 
threefold) in relatives of PC patients, it is estimated that 10% of PCs are due 
to an inherited predisposition, even if it has a lower penetrance unlike familial 
cancer syndromes for breast, colon and melanoma [42; 43; 44; 45]. 
PC often develops without clear early signs or symptoms and the 
eventual manifestations depends on the tumor location within the gland. Up to 
50% of patients presents jaundice, which is more common with patients 
whose cancers are located in the head of the pancreas where tumors can 
cause obstruction of the adjacent biliary system [46]. Other common 
manifestations are vague abdominal discomfort, nausea and weight loss. 
Large tumors that advance beyond the pancreas can also cause duodenal 
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obstruction or gastrointestinal bleeding. Steatorrhea can also result from 
obstruction of the pancreatic duct, whereas hyperglycemia and diabetes have 
been associated with early manifestation of disease. Patients with advanced 
disease can also present abdominal and back pain, anorexia, dyspepsia, 
gallbladder enlargement, migratory thrombosis (Trousseaux syndrome), 
subcutaneous fat necrosis (panniculitis), hyperglycemia, ascites and 
depression [45; 47; 48].  
Based on the information about the physiologic development of 
pancreas, it has been found in some tissues that metaplasia can be 
associated with the increased risk of cancer. Pancreatic acinar cells have the 
capacity to undergo metaplasia to a ductal cell phenotype in the setting of 
acute or chronic inflammation, representing an important link to pancreatic 
ductal adenocarcinoma (PDAC). Acinar-ductal metaplasia (ADM) might 
represent reprogramming of a progenitor population, direct transdifferentiation 
of acinar cells to ductal cells, or transdifferentiation via an intermediate cell 
type (potentially a progenitor cell) [49]. Metaplastic acinar structures are 
highly proliferative, express Notch target genes, and exhibit mosaic 
expression patterns for EGFR, ErbB2, and pErk, reminiscent of the PDAC 
precursors [50; 51; 52]. Spontaneous ADM has been described in vitro, 
accompanied by the induction of Pdx1 expression during culture of acinar 
cells [53]. Another relevant transcription factor is Mist1. Mist1 functions as a 
homodimer, and its loss results in ADM in vitro, with accompanying induction 
of cytokeratins K19 and K20. Transgenic mice expressing a dominant-
negative Mist1 undergo ADM in vivo [54]. Collectively, these studies suggest 
that loss of Mist1 initiates metaplasia and that Pdx1 expression fosters ADM.  
 
 
2.2 The genomic landscape of PC 
2.2.1 KRAS (Kirsten Rat Sarcoma Oncogene) 
The better characterized forms of PC almost universally carries one or 
more of four genetic defects. Particularly, ninety percent of tumors have 
activating mutations in the KRAS oncogene. KRAS encodes a small guanine 
nucleotide transferase, GTPase, that in its active GTP-bound form promotes a 
wide range of cellular responses including proliferation, survival, migration 
and metabolism through several effector pathways including the 
Raf/MEK/ERK (MAPK) and PI3K/AKT kinase cascades (Fig. 2.1) [55]. 
Transcription of the mutant KRAS gene produces an abnormal Ras protein 
that is ‘locked’ in its activated form, resulting in the aberrant activation of 
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proliferative and survival signaling pathways. Furthermore, there is evidences 
for an important contribution of autocrine epidermal growth factor (EGF)-
family signalling. This autocrine loop and resulting stimulation of the 
phosphatidylinositol 3-kinase (PI3K) pathway is required for transformation of 
several cell lineages by RAS-family oncogenes. Consistent with the existence 
of such an autocrine loop, pancreatic ductal adenocarcinomas (PDAC), the 
more frequent kind of PC, overexpress EGF-family ligands (such as 
transforming growth factor-α -TGF-α- and EGF) and receptors (EGFR, 
ERBB2, also known as HER2/neu, and ERBB3) [56; 57; 58]. The main 
mutation of this gene is KRAS G12D and in several cases it is used also in in 
vivo models, for example engineered mice in which KRAS is activated 
develop spontaneous PanINs and later PDAC, above all if they are subjected 
to pancreatic constant inflammatory insults (patients suffering from chronic 
pancreatitis have a 16-fold increased risk of developing PC) [59; 60; 61; 62]. 
Even in vitro fibroblast expressing KRASG12D exhibit elevated Ras-GTP levels 
with the association of enhanced proliferative properties and escape from 
premature senescence [63]. The activated mutation of KrasG12D could be one 
of the earliest genetic abnormalities of pancreatic neoplasia and is sufficient 
to initiate the transformation of pancreatic ductal cells to PanINs, but, to 
guarantee tumor development in vivo, it is usual to induce chronic pancreatitis 
[64]. Several reports show that the most efficient method to induce 
pancreatitis is the use of caerulein, a CCK analog that binds and activates the 
CCK receptor. There are two distinct CCK receptor subtypes, namely CCK1 
(previously named CCKA) and CCK2 (previously named CCKB) receptors. 
CCK receptors are G-protein-coupled receptors initiating transient Ca2+ 
oscillations by activating phospholipase C and induction of inositol 
triphosphate (IP3)-dependent Ca2+ release from endoplasmic reticulum in 
pancreatic acinar cells. CCK1R mediates for example the secretion of 
pancreatic digestive enzymes and may also be involved in the regulation of 
satiety and feeding behavior, while CCK2R stimulate gastric acid production. 
CCK1R has a role in the exocrine effects of cerulein such as amylase 
secretion. However, CCK2R is now recognized to mediate the mitogenic and 
anti-apoptotic effects of gastrin on gastrointestinal and pancreatic cells. In a 
pancreatic tumor cell line expressing the endogenous CCK2R, the 
proliferative effects of the CCK2R have been shown to be induced by the 
activation of the Jak2/Stat3 pathway by this receptor [65]. Caerulein-induced 
acute pancreatitis is a well-studied animal model in which this substance 
causes an edematous pancreatitis. Initiation of acute inflammation is 
mediated through premature intracellular activation of zymogens in the acinar 
cells, leading to acinar death and an inflammatory response associated with 
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mild pancreatic edema [66; 67]. Interestingly, oncogenic K-Ras activation is 
rarely observed in human endocrine tumors and this may in part explain the 
concept that tumor mainly arises from the acinar cell compartment of the 




Figure 2.1: The Ras activation cascade [69]. 
 
2.2.2 CDKN2A (Cyclin-Dependent Kinase inhibitor 2A) 
Activation of KRAS alone in the pancreatic epithelium led to the 
development of PanINs, highlighting the need for additional cooperating 
events to promote tumor progression to the malignant PDAC stage. In a 
number of studies, additional genetic alterations have been combined with 
activation of KRAS to identify cooperating events context of KRAS-dependent 
pancreatic tumorigenesis [70]. The inactivation of the CDKN2A gene is the 
resultant loss of the p16 protein, a regulator of the G1-S transition of the cell 
cycle, and a corresponding increase in cell proliferation. The inheritance of 
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mutant CDKN2A alleles confers a 13-fold increased risk of pancreatic cancer. 
Loss of CDKN2A function is brought by mutation, deletion or promoter 
hypermethylation and occurs in 80/95% of sporadic pancreatic 
adenocarcinomas. CDKN2A loss is generally seen in moderately advanced 
lesions that show features of dysplasia. The locus 9q21 encodes two tumour 
suppressors: INK4A (INhibitors of CDK4) and ARF (the Alternate Reading 
Frame protein product of the CDKN2A locus), via distinct first exons and 
alternative reading frames [71; 72; 73]. INK4A inhibits CDK4/CDK6-mediated 
phosphorylation of RB (retinoblastoma), thereby blocking entry into the S 
phase of the cell cycle; ARF stabilizes p53 by inhibiting its MDM2 (Mouse 
double minute 2 homolog)-dependent proteolysis. INK4A seems to be the 
more important PC suppressor, as germline and sporadic mutations have 
been identified that target this protein. When primary cells are placed into 
culture, INK4A-transcript expression is induced and this can be considered a 
stress response to the inappropriate growth environment that is associated 
with in vitro culture [74; 75]. This induction by environmental stress and 
aberrant proliferative signals provides a plausible basis for the tumour-
suppression function of INK4A, although the relationship of this phenomenon 
to cancer suppression in vivo is not established. Other studies have 
implicated INK4A in the cellular response to DNA damage in vivo, so the 
absence of INK4A might also contribute to the chemoresistance of pancreatic 
adenocarcinoma [76]. Notably, while KRAS mutations are often detected in 
non-neoplastic states, such as chronic pancreatitis and, possibly, in normal 
pancreas, loss of INK4A usually occurs only in later stages of pancreatic 
neoplasia [77; 78; 79]. Although loss of INK4A probably facilitates the 
oncogenicity of activated RAS alleles, as shown in animal models, its 
occurrence later in pancreatic tumour progression indicates that the 
intersection of these pathways might require other events, such as disrupted 
contacts with the extracellular matrix or elevations in the level of activated 
KRAS [80]. 
 
2.2.3 TP53  
The TP53 tumor-suppressor gene is mutated, generally by missense 
alterations of the DNA binding domain, in 50%–75% of tumors. In general, 
TP53 functions as a heterotetrameric complex that transactivates key target 
genes in response to a variety of cellular insults, resulting in cell cycle arrest 
or apoptosis. TP53 mutations arise in later-stage PanINs that have acquired 
significant features of dysplasia, reflecting the function of TP53 in preventing 
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malignant progression, permitting, in this way, cells to bypass DNA damage 
control checkpoints and apoptotic signals and contributing to genomic 
instability [81]. In contrast to many other cancer types, in PC there does not 
seem to be a reciprocal relationship in the loss of CDKN2A and TP53. The 
initiation of pancreatic tumorigenesis by endogenous KRASG12D expression in 
the context of Trp53R172H greatly hastens the development of locally invasive 
and widely metastatic PDAC that faithfully recapitulates all of the extant 
features of the human disease [82]. Cytogenetic studies have provided 
evidence that telomere dynamics might contribute to this genomic instability 
[83]. Although reactivation of telomerase is crucial to the emergence of 
immortal cancer cells, a preceding and transient period of telomere shortening 
and dysfunction might also contribute to carcinogenesis by leading to the 
formation of chromosomal rearrangements through breakage–fusion–bridge 
cycles. The survival of cells with critically short telomeres (crisis), which 
continue to go through breakage–fusion–bridge events, is enhanced by 
inactivation of the p53-dependent DNA-damage response, allowing the 
acquisition of oncogenic chromosomal alterations. Studies in the telomerase-
knockout mouse support this model, as telomere dysfunction and p53 loss 
cooperate to promote the development of carcinomas in multiple tissues. An 
analysis of a large series of human pancreatic cancer cell lines revealed that 
telomeres were frequently lost from chromosome ends and that anaphase 
bridging occurred, indicating that persistent genomic instability is associated 
with critically short telomeres. Telomere dysfunction was an early step in the 
pathogenic process. Moreover, studies of PDAC revealed that tumors have 
shortened telomere length and that the activation of telomerase is a late event 
[84; 85; 86; 87].  
 
2.2.4 SMAD4 
The deleted in pancreatic carcinoma 4 gene (DPC4, also known as 
SMAD4/MADH4 - mothers against decapentaplegic homolog 4 -) is lost in 
about 50% of pancreatic cancers, resulting in aberrant signaling by the 
transforming growth factor-β (TGFβ) cell surface receptor. This gene maps to 
chromosome 18q21 [88]. The pathogenic role of SMAD4 inactivation is 
strongly supported by the identification of inactivating intragenic lesions of 
SMAD4 in a subset of tumors. SMAD4 seems to be a progression allele for 
pancreatic adenocarcinoma, as its loss occurs only in later-stage PanINs and 
it has become a predictor of decreased survival in pancreatic 
adenocarcinoma [89; 90; 91]. In a study using human pancreatic cancer 
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samples from primary and metastatic lesion, mutations in the DPC4 gene 
have been associated with higher metastatic potential [92]. The mechanism 
by which SMAD4 loss contributes to tumorigenesis is likely to involve its role 
in TFG-β mediated growth inhibition. TGF-β can behave as both a tumor 
suppressor and a tumor promoter. Its tumor suppressor function can be 
explained largely by its ability to inhibit proliferation of normal epithelial and 
lymphoid cells by either blocking the G1–S cell cycle transition (from which 
most human cancers originate) and to induce apoptosis [93]. However, late-
stage human carcinomas often become resistant to TGF-β growth inhibition 
and, in addition, secrete elevated levels of this growth factor [94]. But, by now, 
the roles of TGF-β signaling in pancreatic adenocarcinoma pathogenesis are 
not well defined: its role can be well illustrated as a tumor suppressor pathway 
by the presence of chromosomal deletions and mutations in DPC4 in 55% of 
pancreatic tumors, a tumor suppressor that has been implicated in mediating 
the growth inhibitory and antiangiogenic effects of TGF-β [88; 95; 96]. This 
cytokine shows inconsistent effects on cultured cell lines with respect to cell 
proliferation rates and dependency on SMAD4 status for TGF-β 
responsiveness. Furthermore SMAD4 loss is also likely to contribute to tumor 
progression through effects on the interaction of tumor with stroma [97; 98; 
99; 100]. Particularly, heterotypic microenvironmental cellular interactions 
seem to be important in the pathogenesis of pancreatic adenocarcinoma. 
Notably, these tumors show a marked proliferation of stromal fibroblasts and 
deposition of extracellular matrix components such as matrix 
metalloproteinases and collagens (desmoplasia) [101].The role of this 
process in cancer pathogenesis remains uncertain, as it is not well 
established whether the response is part of the tumorigenic programme or 
whether it represents a form of host defence against the tumor. Recent 
evidence indicates that the carcinoma cells direct the desmoplastic response 
and that TGF-β contributes to this process [102]. There are suggestions that 
SMAD4 loss might be permissive for these effects, notably, Smad4-deficient 
tumors show increased growth and invasiveness in this model. Another role 
for SMAD4 in regulating heterotypic interactions is indicated by experiments 
in which Smad4 is reintroduced into some pancreatic adenocarcinoma cell 
lines. In these experiments, Smad4 blocks tumorigenic growth in 
immunodeficient mice by inhibiting angiogenesis, but does not affect cell 
sensitivity to TGF-β [96]. These concepts are consistent with recent studies 
showing that cancers ‘programme’ an oncogenic stroma that, in turn, 
contributes to tumor growth through paracrine signaling, angiogenesis and 
protection from immune attack [103; 104]. 
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Generally, transgenic mouse models which are commonly used are 




Table 2.1: Mouse models of pancreatic carcinoma [105] 
 
2.3 Staging of PC 
In 1905, S.P.L. Hulst described for the first time small microscopic 
lesions in the pancreas which are now described as “pancreatic intraepithelial 
neoplasia (PanIN)”. PanIN lesions are noninvasive epithelial proliferation 
within the smaller pancreatic ducts and they are graded histologically as 
PanIN-1 (low-grade), PanIN-2 (intermediate-grade) or PanIN-3 (high-grade) 
characterized by columnar to cuboidal cells with varying amunts of mucins 
and based on the degree of architectural and cellular atypia present in the 
lesion (Fig. 2.2) [106]. 
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Figure 2.2: A normal pancreatic duct (A) and multiple PanIN lesions (B-F). PanIN-1 
(B), PanIN with associated lobulocentric atrophy (B and C), PanIN-2 (E), and PanIN-3 
(F), all hematoxylin and eosin images [107]. 
 
 
Generally PanIN lesions are not detected macroscopically and are 
clinically silent. PanIN-1 is characterized by two early stages: PanIN-1A and 
PanIN-1B which show minimal cytological and architectural atypia. PanIN-2 
lesions show mild to moderate cytological atypia with frequent papillary 
formation and also nuclear abnormalities for example enlargement, some loss 
of polarity, crowding. PanIN-3 is the most severe lesion with abnormal cell 
mitosis and budding into lumen [108]. Paralleling this histologic progression is 
a genetic progression. PanIN-1 and PanIN-2 often harbor genetic alterations 
in the KRAS and p16/CDKN2A genes, whereas PanIN-3 lesions and invasive 
adenocarcinomas, in addition to genetic alterations in KRAS and 
p16/CDKN2A, also often harbor mutations in TP53 and SMAD4 (Fig. 2.3) 
[109; 110]. High-grade PanINs, however, are rarely found, unless there is an 
associated invasive pancreatic cancer or the patient which has a strong family 
history of PC; these observations support the hypothesis that PanIN lesions 
are precursors to invasive adenocarcinoma [111; 112; 113].  
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Figure 2.3: Genetic progression model of pancreatic adenocarcinoma [17] 
 
The second major precursor lesion to be identified in the pancreas 
was the intraductal papillary mucinous neoplasm (IPMN). IPMNs arise in the 
larger pancreatic ducts and, as the name suggests, they are typically papillary 
and often produce copious amounts of mucins. IPMNs are, by definition, 
larger than PanINs (>1.0 cm, with respect to <0.5 cm for PanINs) [3]. As is 
observed with PanINs, low-grade IPMNs often harbor KRAS and 
p16/CDKN2A gene mutations, high-grade IPMNs harbor further mutations in 
TP53 and SMAD4. When an adenocarcinoma arises in association with an 
IPMN, the IPMN and the invasive carcinoma almost always harbor the 
samegenetic alterations, supporting the hypothesis that IPMNs are a 
precursor to invasive adenocarcinomas [114]. Far less common than IPMNs, 
are the Mucinous cystic neoplasms (MCNs), they are large mucin-producing 
precancerous lesions of the pancreas that almost always arise in the body of 
tail of the gland and commonly arise in women. In contrast to IPMNs, MCNs 
do not significantly involve the pancreatic duct system. However, like IPMNs, 
MCNs can progress to adenocarcinoma. The KRAS, p16/CDKN2A, RNF43, 
TP53 and SMAD4 genes have all been reported to be mutated in MCNs [3; 
114]. Finally, it can be mentioned some small cancer lesions, rarely 
encountered outside of screening trials. There have been several reports of 
long-term survival of patients with surgically resected small, lymph node 
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2.4 Biomarkers for detection of PC 
One of the main difficulties about PC detection is just the lack of 
reliable screening tests, either molecular or imaging based. Commonly used 
imaging studies as abdominal CT (computer tomography) or MRI (Magnetic 
Resonance Imaging) are still inadequate for diagnosing PC at an early stage 
since they do not reliably detect tumors smaller than 1-2 cm [116]. The mucin-
associated carbohydrate antigen CA 19–9 is a biomarker of PDAC with 
limited clinical utility in the screening setting. CA 19–9 has demonstrated 
modest effectiveness in the screening of symptomatic individuals with a range 
of 70–90% of cases. But the principal limitations of CA 19–9 include its 
frequent elevation associated with nonmalignant conditions such as 
pancreatitis and obstructive jaundice and its inability to detect many early 
stage malignancies [117; 118]. These limitations of CA 19–9 have led 
investigators to search for alternative biomarkers for use in screening for 
PDAC. For example, a panel of 7 proteins (ALCAM, ICAM-1, LCN2, TIMP-1, 
REG1A, REG3 and IGFBP-4) with or without the addition of CA 19–9, 
selected based on findings in a mouse model, was able to discriminate 
human PC cases from matched controls in a small group of presymptomatic 
and prediagnostic blood samples [119]. Biomarker profiles indicative of a 
specific cancer include not only those factors produced by the tumor itself but 
also represent the systemic response to the growing tumor including acute 
phase reactants, inflammatory cytokines, growth and angiogenic factors, etc. 
An accurate panel of circulating levels of significant biomarkers in patients 
diagnosed with PC, benign pancreatic disease and healthy control individuals 
is reported in table 2.2: 
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Table 2.2: Biomarkers, their concentration and significance in healthy individuals and 
patients with benign lesions or PDAC [120]. 
 
Other markers not expressed in normal ductal cells but observed in 
low-grade to high-grade PanIN are tumor-associated glycoproteins as CEA 
and CA125. Conventional PDACs show also at least focal mucin positivity: 
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the MUC protein are variously expressed in all types of ductal neoplasms. 
MUC1 is expressed in the 86% of cases, MUC3, 4, 5AC in the 71%, MUC6 (a 
pyloric gland mucin) in 20% and MUC2 in 6% [3; 121].  
 
2.5 Treatment of PC 
The progress in the development of systemic treatment of advanced 
PC has been slow. The antinucleoside gemcitabine is the standard of care: 
when it is combined with either cisplatin or oxaliplatin in individual trials, no 
benefits over single gemcitabine could be shown [122; 123; 124; 125]. Other 
data showed that gemcitabine combined with 5-fluoruracil (5-FU) might 
provide a therapeutic advantage over gemcitabine alone [126]. But if 
gemcitabine still represents the first-line chemotherapeutic agent for the 
advanced and also metastatic pancreatic cancer, with marginal survival 
advantage and amelioration of disease-related symptoms, resistance 
phenomena have been increasing in recent years and its effectiveness has 
been reduced to <20% [127; 128]. Resistance to gemcitabine treatment is 
mainly attributed to an altered apoptotic threshold in PC cells [129]. Several 
experimental reports showed that one of the proteins involved in the 
acquisition of resistance is MUC4, a member of the mucin family. This family 
comprises the secreted and membrane-bound forms of protein with a high-
molecular weight and heavy O-glycosilation sites that participate in the 
lubrification of luminal epithelial surface and protection against external 
insults. Among them MUC4, which is constituted by the extracellular and 
transmembrane domains and a short cytoplasmic carboxyl-tail, is considered 
as mediator of intracellular signals involved in cancer development. MUC4, 
together with other mucins, can play a role for the sustained growth, survival 
and metastasis of cancer cells at distant tissues and organs and drug 
resistance [130; 131]. MUC4 is normally absent in the pancreas but an 
aberrant expression is detected both in PanIN and in its relative advanced 
cancer [132; 133]. The mechanism by which MUC4 can reduce the apoptotic 
grade is based on its contribution to enhanced cellular proliferation through its 
interaction with the epidermal growth factor receptor tyrosine kinase (ErbB2) 
with subsequent activation of Erk and Akt signaling pathways [134]. 
Particularly, using MUC4 knockdown and overexpression cancer cell models, 
this protein has been shown to modify tumorigenity and metastasis by altering 
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2.5.1 The importance of the PC microenvironment in therapy 
The microenvironment of pancreatic adenocarcinoma has a complex 
role in tumor growth and therapeutic response [138].These cancers are 
characterized by a dense stroma consisting of proliferating myofibroblasts 
(pancreatic stellate cells) and deposition of type I collagen, hyaluronic acid 
and other extracellular matrix components, as well as multiple types of 
inflammatory cells, including macrophages, mast cells, lymphocytes and 
plasma cells. Factors that are produced in the stroma, such as connective-
tissue growth factor, may directly contribute to the survival of tumor cells 
[139].The fibrous stroma may contribute to this reduced blood flow and its 
high interstitial pressure may impair drug delivery [140]. The stroma is not 
only a mechanical barrier but also constitutes a dynamic compartment 
critically involved in the process of tumor formation, progression, invasion and 
metastasis; stromal cells express multiple proteins such as Cox-2 
(Cyclooxygenase-2), PDGF (Platelet Derived Growth Factor) receptor, VEGF 
(Vascular Endothelial Growth Factor), SDF (stroma-derived factor), 
chemokines, integrins, SPARC (secreted protein acidic and rich in cystein) 
and hedgehod pathway elements, among others, that have been associated 
with a worse prognosis and resistance to treatment [141]. Encapsulation of 
therapeutic agents using albumin nanoparticles (nab) overcomes biological, 
physical and chemical obstacles, such as the stroma [142]. This allows the 
administration of insoluble lipophilic agents, as nab- paclitaxel which is an 
amorphous and crystalline form of paclitaxel bound to albumin (at a 
concentration of 3–4%). The biological activity of nab-paclitaxel is solely 
based on its affinity for the mitotic spindle; albumin confers tropism to cancer 
tissue, while paclitaxel binding stabilizes microtubules and prevents the 
assembly that is necessary for mitosis, transport and intracellular motility 
[143]. Nab-paclitaxel therapy caused more cases of complete regression, 
increased survival and delayed recurrence. This result may be explained by 
the ability of nab-paclitaxel to achieve higher intratumoral concentrations (up 
to a 33% increase) compared to conventional paclitaxel. These results could 
also be explained by of the absence of conventional solvents (which inhibit 
the albumin dependent pathway), decrease in the generation of micelles, 
and/or the retention of nab-paclitaxel in tumor microvessels [144; 145]. 
Several studies suggest that SPARC functions as a stromal chaperon playing 
a critical role in collagen turnover in PC, it is the target of nab-paclitaxe [141]. 
Moreover, data obtained from genetically engineered mouse models indicate 
that nab-paclitaxel antitumour effects were dose-dependent but SPARC 
independent, thereby inducing apoptotic cell death in the tumor rather than 
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stromal cells. On the other hand, as inhibitors of the hedgehog pathway stop 
the desmoplastic reaction, the stroma involution observed after nab-paclitaxel 
treatment in PDAC may resemble regression of fibrotic matrix found with this 
drug in others settings. As reactive stromal cells convert extracellular matrix 
(ECM) into inert tissue with deficient non-angiogenic vasculature and taxanes 
suppress breast cancer metastasis through abrogation of stromal cells (α-
smooth muscle), it would be tempting to speculate that there could be a 
functional interaction between nab-paclitaxel and stromal cells in neoplastic 
diseases. However, the molecular mechanisms governing this hypothetical 
link have not been clarified yet [146]. 
In conclusion, it is possible to summarize the current therapeutic regimens as 
it follows: 
FOLFIRINOX (5-FU, irinotecan, and oxaliplatin),  
FOLFOX (5-FU and oxaliplatin), 
Gem-nab (gemcitabine and nab-paclitaxel),  
Gem-Ox (gemcitabine and oxaliplatin),  
Gem-Cap (gemcitabine and capecitabine),  
GTX (gemcitabine, docetaxel, and capecitabine) [147].  
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THE EPITHELIAL TO MESENCHYMAL TRANSITION 
 
3.1 Introduction 
The epithelial to mesenchymal transition (EMT) is a key process in the 
embryonic development, when, to provide the organ formation, the first 
epithelial cells change their own phenotype to generate the mesoderm. The 
EMT has been characterized starting from ’80 years, but in the 1995 Elizabeth 
Hay was continuing to describe it as “epithelial to mesenchymal 
transformation”, only later the term “transformation” was replaced with 
“transition”, by consent to the reversible features of the process (MET), when 
the cells of the mesoderm are subjected to a new transformation to create 
epithelial organs, like kidney or ovary. But the EMT is still less characterized 
[148; 149]. Epithelial cells form layers that are closely adjoined by specialized 
membrane structures, such as desmosomes, tight, gap and adherens 
junctions. They are polarized cells with adhesion molecules as cadherins and 
certain integrins in specific apical-basolateral zones. These molecules are 
involved in the organization of cell-cell junctions as a lateral belt, the polarized 
organization of actin cytosckeleton and the presence of the basal lamina at 
the basal surface. Epithelial cells have not motility, they can move only within 
the epithelial layer. On the other hand, mesenchymal cells, characterized by a 
strong migratory ability, do not form as organized cell layer, are not polarized, 
have not adhesion molecules and they show spindle-shape, named fibroblast-
like morphology [150].  
During EMT different phenomenon participate like the activation of 
several transcriptional factors, the production of enzymes of (ECM 
degradation and cytoskeleton proteins; it changes the expression of 
microRNA. Beyond the physiological elements, EMT conducts an important 
role also in the tissue reparation and in pathological stresses like inflammation 
and advanced tumor state. For these reasons, it is possible, by now, to 
classify 3 types of EMT (Fig. 3.1). 
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Figure 3.1: Three types of EMT are identifiable depending on the phenotype of 
generated cells. 
 
3.1.2 Type 1 EMT: mesenchymal 
During the embryonic implantation, EMT enhances the invasion of the 
endometrial cells, which can, in this way, anchor to the placenta. Then, during 
the gastrulation, the epithelial cells begin to differentiate to form mesoderm 
and ectoderm. Epithelial cells answer to the Wnt pathway which is activated 
by the TGFβ; the other important transcriptional factors are Snail that, for 
example, represses the E-cadherin, a cell-cell adhesion molecule [151]. The 
other genes which are involved above all in the neural crest formation starting 
from primary neuroepithelial cells are Sox, Slug, FoxD3 (Forkhead box D3) 
but also FGF, BMP and c-Myb [152]. 
 
3.1.3 Type 2 EMT: epithelial-fibroblast transition (EFT) 
Fibrosis is mediated by inflammatory cells and by fibroblast which 
product the components of the ECM like collagene, laminine, elastine, 
tenacine, above all in organs like intestin, kindney and liver EMT is associated 
to the fibrosis. In these phases the proteins that are considered markers of 
the fibrotic EMT are FSP1 (Fibroblast-specific protein 1, also named S100A4), 
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αSMA (α Smooth muscle actin), collagene I, the other markers like desimne 
and vimentine are utilized like sensors of chronic inflammation in the cited 
organs [153]. In the microvascular endothelial cells the EMT, defined as 
EndEMT, appears in a post-ischemic situation; in this inflammatory contest, 
cells lose the expression of CD31 and the integrin αVβ3, following the effect 
of the TGFβ [154; 155]. Other examples of EMT are reported also in patients 
with kidney fibrosis and Crohn disease where cells first epithelial expressed 
cytokeratines, αSMA, vimentine and ZO-1 (Zona Occludens 1) [156; 157].  
3.1.4 Type 3 EMT: metastatic 
The characteristic elements of EMT with the relative loss of epithelial 
markers has been observed in different pathological states, including the 
epithelial tumor progression. The analysis of the molecular mechanisms at the 
base of the plasticity of the epithelial cells suggested that the inappropriate 
expression of mesenchymal markers enhances migration and invasion. 
Therefore, the development of EMT in cancer progression correlates with 
advanced states and poor prognosis [158].  
 
 
Figure 3.2: Contribution of EMT in tumor progression [151]. 
 
Like summarized in figure 3.2, the progression from normal epithelium 
to the invasive carcinoma proceeds through several passages which include 
the loss of cell polarity, the detachment from basal membrane; the 
composition of this membrane changes with respect to the cell-ECM 
junctions. The following step concerns the input in the blood stream with the 
intravasation and they dissemination, the attachment in a secondary site and 
the formation of micro- and macrometastases. In this phase cells become 
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3.2 The effectors of EMT  
Among the components which are regulated during EMT there are 
epithelial adhesion proteins such as E-cadherin, α- and γ-catenin, about the 
last one, both transcriptional and transductional expression is repressed. 
There are three groups of transcriptional factors activated during EMT. The 
first one includes Snail 1 and 2, zinc finger proteins which are capable to 
directly regulate the E-box domain of E-cadherin promoter by metilation. 
Recently, it has been shown that Snail 1, in human breast cancer cells, MCF-
7 and MDA-MB-231 contributes to the activation of the protein MT1-MMP 
(Membrane-tethered poteases – Membrane metallo-proteases), MT2-MMP 
and MMP9, on the contrary Snail 2 directly acts on MT4-MMP e MMP2 [161; 
162].  
The second group is formed by Zeb (Zinc Finger E-box binding 
homeobox) 1 and 2, which equally repress E-cadherin, not directly but 
through a negative feedback, involving also the action of miRNA200. Both 
groups act also in down-modulation of ZO-1 and claudin. Through 
trandendothelial migration assay, it has been shown that the expression of 
Zeb1 enhances human prostate cancer cells PC3 to leave the extracellular 
barrier and enter the blood stream [163; 164]. 
Finally, the third group is composed by the bHLH (basic Helix-Loop-
Helix) factors as Twist 1 and 2, E12/E47; particularly Twist1 suppresses E-
cadherin activating Snail but acts also alone like mediator of cell invasion 
[159]. Generally, Twist1 is a mediator of proteases like MT-MMPs, ADAMs, 
MMPs which organized in the invadopodia, subcellular structures rich of actin, 
assigned to the invasion process, above all if it is linked to the tumor 
progression. The invadopodia formation is mediated also by a autocrine loop 
of PDGF (Platelet Derived Growth Factor), just induced by Twist, on the own 
receptor PDGFRα [165]. 
 
3.3 Markers of EMT 
A variety of biomarkers have been used to demonstrate all three 
subtypes of EMT. In recent years, changes in the level of expression of 
different cadherins, so-called cadherin switches, have been increasingly used 
to monitor EMT. Indeed, the cadherin switch from E-cadherin to N-cadherin, 
which is expressed in mesenchymal cells, fibroblasts, cancer cells, and neural 
tissue, has often been used to monitor the progress of EMT during embryonic 
development and cancer progression. In addition, because OB-cadherin is a 
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more definitive marker for activated fibroblasts, an E-cadherin–OB-cadherin 
switch is of interest for type 2 EMT associated with fibrogenesis [166; 167].  
An integrin switch also reflects alterations in cell-ECM interactions, 
facilitating EMT. For example, in colon carcinoma, only cancer cells that have 
undergone type 3 EMT to a metastatic phenotype express high levels of β6 
integrin, the normal epithelial and noninvasive cancer cells have low-level 
expression of this protein [168]. Increased expression of α5 integrin also 
correlates with the metastatic potential of B16F10 melanoma cells and EMT 
suggesting that also this integrin plays a role in each subtype of EMT [169].  
Another EMT marker that reflects adaptation to the altered ECM 
microenvironment associated with EMT is the collagen-specific receptor 
tyrosine kinase DDR2 (discoidin domain receptor tyrosine kinase 2). Upon 
binding to type I or type X collagen, DDR2 mediates upregulation of MMP1 
and cell motility [170; 171].  
A controversial marker of EMT is vimentin, the protein of intermediate 
filaments, which is expressed in various cells, including fibroblasts, 
endothelial cells, cells of the hematopoietic lineages, and glial cells. However, 
because adult epithelial cells transiently express vimentin in response to 
various insults, it is not considered a marker of type 2 EMT. By contrast, 
vimentin is commonly used to identify cells undergoing type 3 EMT in 
cancers. This information is based on a positive correlation of vimentin 
expression with increased invasiveness and metastasis [172].  
β-catenin is another component of the adherence junctions. It forms a 
bridge between the cytoplasmic domain of the cadherins and the actin 
cytoskeleton. The level of β-catenin in the cytoplasm are regulated through its 
recruitment to cadherin-binding partners or ubiquitination and subsequent 
degradation. Particularly, the interaction between β-catenin and E-cadherin 
are regulated by tyrosine phosphorylation in the carboxyl terminal of the first 
protein. These reactions destabilize the cadherin- β-catenin bond and 
promote loss of intracellular adhesion. Conversely, dephosphorylation of β-
catenin residues increases the activity of E-cadherin and β-catenin and α-
catenin reassembly. After tyrosine phosphorylation of β-catenin, its cytosolic 
pool is increased and may increase the transcriptional activity of the β-
catenin-TCF (T Cell Factor) complex. So, β-catenin has been used as a 
marker of EMT in various studies of embryonic development, cancer, and 
fibrosis, in particular in cells that undergo EMT [153; 173; 174; 175]. 
Fibronectin is a high-molecular weight glycoprotein that serves as a 
scaffold for fibrillar ECM [176]. Because it is one of the first molecules to 
appear when the fibrillar ECM is formed, it has been used as an indicator of 
type 1 EMT associated with gastrulation, palate fusion, and neurulation [177]. 
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Even though fibronectin is an integral constituent of the fibrotic ECM 
associated with tissue fibrosis and the desmoplastic stroma in tumors, the 
utility of fibronectin as a type 2 and type 3 EMT biomarker is limited, in part, 
because it is produced by various cell types, including fibroblasts, 
mononuclear cells, and epithelial cells. Both type 2 and type 3 EMT, however, 
are associated with increased fibronectin expression in vitro [178]. 
Of the principal basement membrane constituents (type IV collagens, 
laminin, nidogen, and sulfated proteoglycans) that are downregulated during 
EMT, laminin is best established as a biomarker of the process. Laminins are 
heterotrimeric glycoproteins composed of one α chain, one β chain, and one γ 
chain, 15 different heterotrimers are known [179]. Both type 1 and type 2 EMT 
are associated with downregulation of laminin1 in vitro and disruption and loss 
of laminin1 in vivo [180; 181]. By contrast, upregulation of laminin 5 (α3β3γ2) 
is associated with type 3 EMT in cancer and type 2 EMT in tissue fibrosis 
[182]. 
The main EMT markers are listed in table 3.1. 
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Table 3.1: The main markers for EMT [159] 
 
 
3.4 The inducers of EMT 
There are multiple signals from the microenvironment which act on the 
EMT and they can be both cell- and tissue-specific. Beyond the pathways of 
Wnt and Notch, important molecules in embryonic development, TGF-β 
participates, too. This last factor is the main member of a family of 40 
pleiotropic cytokines, involved in some processes such as proliferation, 
apoptosis, differentiation, migration, stem-like phenotype, regulation of 
immune responses. Three isoforms are, by now, better characterized (TGF-
β1, 2, 3) because ubiquitous. The pathways activated by the interaction of 
TGF-β with the receptor are mediated from the SMAD, a family composed by 
8 proteins classified as R-SMAD (Receptor-activated SMADs), as SMAD 1, 2, 
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3, 5, 8; coSMAD (common mediator SMADs) as SMAD4 and I-SMAD 
(Inhibitory SMADs), SMAD 6, 7. Without TGF-β the SMAD are not active, 
instead, answering to its effect, R-SMAD form heterotrimeric complexes with 
SMAD4 which organize with other factors in the nucleus to regulate gene 
expression. Another kind of pathway down line of TGF-β is defined not 
canonical and utilizes other regulatory proteins like MEK/ERK, GTPasi Rho-




Figura 3.3: Pathways of TGF-β dependent or not from SMADs [186]. 
 
 
TGF-β shows antiproliferative effects on normal epithelial, endothelial, 
neural cells such as on the immune system, particularly the T linfocyte, in 
which it regulates the expression of genes that are involved in cell cycle 
phases G1/S. For example, TGF-β induces the expression of inhibiting 
molecules of the Cdk (Cicline-dependent kinases) as CDKN2B or CDKN1A, 
on the contrary, it inhibits the oncogene expression like c-Myc and ID 1, 2 and 
3 (Inhibitor of DNA binding protein) [186]. An experimental example can be in 
KO (Knock Out) mice for Smad3 in which the rate of growth of keratinocytes 
is enhanced and also wound healing can repare more rapidly [187]. 
Furthermore, in hepatoma cells, is has been shown that TGF-β induces 
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apoptosis through the proteins SMAD and the DAPK (Death Associated 
Protein Kinase) [188]. Therefore, during tumor development, the pathway of 
TGF-β loses its function following some mutations of TGF-βR1, TGF-βR2, 
SMAD 2, 3 and 4, particularly in gastric, colonrectal, prostate and pancreatic 
cancers [189]. But when neoplatisc cells cross the check mechanisms and 
begin the dissemination, starting from the primary tissue, TGF-β participates 
as promoter of the invasion and of metastatisation. In fact, the effect of TGF-β 
is upstream of yet cited transcriptional factors such as Snail, Slug, Zeb1 and 
2, Twist. For example, the signal of SMAD2 keeps repressed the E-cadherin, 
cingulin, claudin-4 and calicrein-1 expression [190; 191]. Numerous 
experiments allowed to create a sort of parallelism between TGF-β and 
hypoxic condition, which constitutes an important part of tumorigenesis and 
ends with the activation of HIF1α (Hypoxia Induced Factor 1 α) and of uPAR 
receptors (uroknase Plasminogen Activator receptors),  considerable 
conditions in the acquisition of a mesenchymal phenotype, in fact some 
possible reoxygenation can conduct to MET [192]. Other important factors in 
EMT (and in its reversion), both inducers like intracellular signal trasnductors, 
chromatin regulation molecules, transcriptional factors, splicing regulators and 
miRNA and mediators as cell-cell or cell-ECM adhesion molecules, 
organizers of cytoskeleton remodeling, chemokines and cytokines and stem-
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Figure 3.4: Summary representation of EMT/MET program [193]. 
3.5 EMT in pancreatic cancer progression  
Both chronic pancreatitis and pancreatic cancer tissues demonstrate 
active EMT profile [194]. The EMT phenomenon in PC cell lines and surgically 
resected tissues has been documented, for example it was found, in vitro, that 
L3.6pl, Colo357, BxPC3, HPAC, CFPAC-1 and SU86.86 cells expressed high 
levels of epithelial marker E-cadherin; however, MIA PaCa-2, PANC-1, AsPC-
1, Hs766T and MPanc96 cells had high level of expression of mesenchymal 
markers like vimentin and ZEB1. Among those cell lines, gemcitabine-
resistant PC cells such MIA PaCa-2, PANC-1 and AsPC-1 showed strong 
expression of vimentin, and ZEB-1 suggesting that the gemcitabine-resistant 
cells elicits EMT phenotype which could be in part responsible for drug 
resistance [195; 196]. Importantly, increased expression of fibronectin, 
vimentin, N-cadherin and decreased expression of E-cadherin were 
correlated with invasion, metastasis and poor survival. These results suggest 
that a population of distinct PC cells, which show EMT phenotypes, exists in 
PC and could promote the progression and aggressiveness of PC [197; 198]. 
The expression of N-cadherin is another critical event in EMT; a clear 
mechanism linking the effect of TGFβ with the N-cadherin expression 
explains that, when the TGF-β pathway is activated, SMAD proteins, mainly 
SMAD4, subsequently translocate into nucleus, where they influence, trough 
the SBEs (SMAD binding elements), the expression of several genes, 
including CDH2, encoding for N-cadherin. In fact, the knockdown of SMAD4 
causes a decrease N-cadherin expression with a resulting decrease of 
migration and invasion of human pancreatic ductal epithelial cells and a 
similar result is obtained after CDH2 knockdown [199]. Furthermore, in 
gemcitabine-resistant cells it was found a high expression of HIF1α and, more 
importantly, the inhibition of this factor caused partial reversal of EMT 
phenotype, suggesting that HIF1α was critically involved in gemcitabine-
resistant-mediated EMT [200]. The analysis of EMT statuses, 
clinicopathologic factors and prognoses report a significant correlation 
between EMT status and CA19-9 levels, peritoneal washing cytology, portal 
vein invasion and lymph node metastasis. Multivariate analysis demonstrated 
that perineural invasion, lymph node metastasis and EMT status were 
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The Annexins belong to a family of soluble and hydrophilic proteins 
correlated by their structure, that interact with the plasma membrane, through 
the anionic phospholipids, in a calcium-mediated fashion [202]. They have 
been discovered at the end of 70’s and have been identified both in 
mammalian organisms and in mildews or plants. The name Annexin derives 
from the Latin “adnexio”, meaning their main properties to bind and to keep 
themselves joined to plasma membranes. So two principal parameters are 
important to identify an annexin protein: the capability to interact with the 
negative membrane phospholipids though the Calcium (Ca2+) and the 
presence of a repeated segment of 70 amino acids defined as “annexin 
repetition”. This repetition is particularly preserved in about all annexins, 
instead the NH2-terminal part is more variable. The role of these proteins 
appears quite important, both in cytosol and at the plasma membranes, as 
confirmed by their presence in 65 animal species. Annexins represents by 
now about 2% of all cell proteins [203; 204]. 
 
4.2 Annexin A1 structure 
Annexin A1 (ANXA1) is the first characterized member of the yet 
described annexin family, comprising 12 other members. Its structural nucleus 
is constituted by four homologous segments and is surrounded by a C-term, 
which accommodates the sites binding Ca2+ cations, and an N-term. As 
shown in figure 4.1, the convex side is situated in front of plasma membrane, 
on the other hand, the concave one is accessible for the interactions with the 
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Figure 4.1: Ribbon diagrams of (a) one monomer of recombinant porcine annexin 1 
comprising protein core and the N-terminal domain and (b) human annexin 1 lacking 
the first 32 amino acid residues. The yellow N-terminal helix in (a) is replacing the 
two-turn blue helix in (b). Bound calcium ions are illustrated as yellow spheres [206]. 
 
 
The first annexin described with its crystal structure was the Annexin 
A5, but the first longer annexin studied by high resolution crystallography has 
been just the ANXA1. This one has a N-terminal domain of 44 amino acids, of 
which the first 10-14 represent a site binding S100A11 (Fig. 4.2); particularly, 
this portion comprises phosphorylation sites for Protein Kinase C (PKC) and 
tyrosine-kinases, and other ones for glycosylation, acetylation and proteolysis 
reaction. The C-terminal domain or core presents, between each of its four 
repetitions, segments of 17 amino acids that are specific for the bind to the 
Ca2+ [207; 208; 209].  
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Figure 4.2: In the crystal structure of Ca
2
-free ANXA1 (red), the NH2-terminal-helix, 
which contains the S100A11 binding site (brown), is replacing helix D of the third 
repeat. Ca
2
-dependent membrane binding could be accompanied by a conformational 
change establishing the Ca
2
-bound crystal structure of the ANXA1 core and, most 
likely, a more accessible NH2-terminal domain. As a result, the NH2-terminal domain 
can interact with a second membrane surface or the S100A11 dimer, which itself 
requires Ca
2
 binding to establish an interaction-competent conformation. An 
hypothetical ANXA1/S100A11 heterotetramer would represent an entity capable of 
linking membrane surfaces [210] 
 
The gene of ANXA1 has been the first one to be cloned, it is localized 
on the human chromosome 9, particularly at 9q12-21.2 and codes for a 
protein of 38,71 kDa. The promoter is particularly preserved and presents 
consensus sequences for some molecules [211].  
About its subcellular localization, studies using cell fractionation and 
immunogold labelling indicate that, ANXA1 exists in three distinct pools: (i) in 
the cytoplasm, (ii) embedded in membrane structures, and (iii) attached to the 
outer surface of the plasma membrane [212; 213].  
 
4.3 ANXA1: an anti-inflammatory protein 
Originally named as lipocortin 1, ANXA1 has been first identified as 
protein with anti-inflammatory functions, in fact its promoter is strongly 
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regulated by glucocorticoids, and in several in vitro and in vivo models 
mediates their effects [214; 215; 202]. It is now evident that the association 
between glucocorticoids and ANXA1 is more complex than initially observed. 
Dexamethasone and other steroids regulate the expression of ANXA1 since 
its promoter has a canonical Glucocorticoid Response Element (GRE). More 
delayed augmentation of cell surface expression of ANXA1 is consequent to 
gene activation. [215; 216; 202; 217]. ANXA1 was initially characterized for its 
ability to inhibit prostanoid release, an effect that underlined its efficacy in the 
rat paw oedema model [218; 219]. ANXA1 was also able to elicit an anti-
pyretic response that was clearly associated with an inhibition of 
prostaglandin E2 production in the third ventricle [220]. ANXA1 acts on 
specific enzymes as phospholipase A2 (PLA2), both through direct and 
indirect inhibition [221; 222]. Other inhibited enzymes are the macrophage 
iNOS (inducible Nitric Oxide Synthase) through the induction of Interleukin-
(IL)10 expression, and COX2 [223; 224; 225]. Even if the ANXA1 gene 
deletion does not represent a lethal event, as confirmed in the papers of 
Hannon et al and Yang et al, in null mice for ANXA1 there is an over-
expression of some pro-inflammatory enzymes as iNOS, COX-2 and cPLA2 
above all in thyme and lungs, suggesting that this inducible enzyme could be 
indirectly influenced by this protein [226; 227; 228; 229; 230]. ANXA1 is not so 
abundant within neutrophils, comprising ∼2–4% of total cellular protein, but it 
is the major proresolving agent, inducing both neutrophil apoptosis and their 
phagocytic clearance by macrophages [231; 232; 233]. Furthermore, migrated 
neutrophils upregulate ANXA1 gene activity, contributing to the abundant 
presence of this protein in exudates, as shown in rodent and human settings 
[234; 235]. Again mimicking the action of glucocorticoids, ANXA1 promotes 
inflammatory cell apoptosis associated with transient rise in intracellular 
calcium and caspase-3 activation [236].    
Also in rats, ANXA1 can modulate lipopolysaccharide (LPS)-induced 
neutrophil accumulation [237]. ANXA1 induces anti-
inflammatory/proresolution effects in these cells, including suppression of IL-
6, IL-1β and TNF-α, production of IL-10, negatively regulating phosphorylation 
of p38 [238; 239; 240].     
In the years, lots of studies created a substantial body of evidence that 
suggests that many effects of ANXA1 are exerted through a cell surface 
receptor mediated mechanism. A key paper by Walther et al. [241] implicated 
the formylated peptide (fMLP) receptor subtype FPR in the transduction of the 
ANXA1 signal in leukocytes. FPR1 is a member of a family of G-protein 
coupled receptors expressed in migratory cells and many other tissues, FPR2 
is important in human polymorphonuclear leucocytes (PMN) and ANXA1 
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compete with other receptor known ligands. Endogenous ANXA1 and FPR2 
co-immunoprecipitate is found in murine extravasated PMN in vivo. Acetyl 2–
26, the N-terminal ANXA1 mimetic peptide, retains the ability to promote the 
detachment of adherent leucocytes in FPR1 null mice suggesting that FPR2 
is a candidate receptor for this peptide [241; 242; 243]. The ANXA1/FPR2 
pathway has a central role in the resolution process and in the modulation of 
monocyte recruitment, neutrophil extravasation and apoptosis [244; 245]. 
In conclusion, in cell types including peripheral blood leucocytes 
(PBMC), it has been shown that ANXA1-derived peptides Ac2-26 can inhibit 
antigen-driven cellular proliferation and cytokine production and also other 
effects like classified in table 4.2 [246]. 
 
 
Table 4.1: List of experimental systems where the anti-inflammatory actions of 
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4.4 ANXA1 post-translational modifications 
Lots of ANXA1 functions depends on its post-translational 
modifications, its activity is regulated by many chemical modifications 
including covalent ones. Summarizing the results and recent literature, it can 
be concluded that ANXA1 is phosphorylated by several kinases. This 
phosphorylation is not Ca2+-dependent but the phosphorylated ANXA1 binds 
the phospholipids in a Ca2+-dependent manner: the conformation of ANXA1 
changes by Ca2+ binding followed by the release of the N-terminal domain 
[247]. It was shown by Futter et al. that ANXA1 is a substrate of EGF-R 
kinase in multivesicular bodies (MVBs), important for stimulated EGF-R 
internalization. The ANXA1 phosphorylation has been suggested being 
responsible for the MVBs inward vesiculation induced by EGF-R activation, 
furthermore, ANXA1 phosphorylation is linked with EGF-R internalization 
suggesting that the endosomal EGF-R kinase may be involved in the protein 
phosphorylation [248; 249]. Even if the phosphorylated ANXA1 residue in this 
study is not shown, EGF-R has as the main target the residue Tyr21. Then, 
Varticovski et al. showed that Tyr21 and Ser27 of ANXA1 are phosphorylated 
by protein tyrosine kinases and protein kinases A/C (PKA/C), respectively 
[250]. It was also reported that phosphorylation of Tyr21 in ANXA1 inhibits its 
ability to aggregate chromaffin granules [251; 252]. As shown in figure 4.3, 
Schlaepfer and Haigler have reported that from the Tyr24 to Ser45, these 




Figure 4.3: Schematic representation of the target residues and principal kinases 
involved in ANXA1 phosphorylation. S, T, H and Y are respectively Serine, Threonine, 
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Although PKC and annexins have some features in common, such as 
binding of calcium and phospholipids and association with cytoskeletal 
elements, there are no structural similarities between them. The PKC-
dependent sites are located in a consensus sequence motif (Ser/Thr-Val-
Arg/Lys), interestingly, other annexins, such as ANXAIII, VII, VIII and X, which 
possess the putative PKC substrate motif are also potential substrates for 
PKC [254]. Supporting this aspect, it has been constructed a plasmid with 
mutations on three single nucleotides like A11R, V22K and V36K that cannot 
undergo to phosphorylation and then proteolitic cleavage probably by the 
serin-proteases, proteinases 3, like shown in PMN [255].      
Following the analysis of the most important ANXA1 points of 
modification, is has been shown that Ser27 phosphorylation induces a 
conformational change, which is probably related to the described membrane 
aggregation property [256]. The phosphorylation of ANXA1 on Ser27 is crucial 
for migration to cell surface and maybe to protein externalization; 
glucocorticoids induce rapid serine phosphorylation and membrane 
translocation of ANXA1 via a novel glucocorticoid receptor (GR)-dependent 
mechanism, which requires MAPK, PI3K and Ca2+-dependent PKC pathway 
and it is now clear that the phosphorylation of Ser27 residue and protein 
migration to the cell membrane are implicated in hormones release. Finally, 
the serine phosphorylation is essential not only for the protein migration but 
also for the involvement of isoprenyl lipids [257; 258; 259; 260]. 
Not only phosphorylations appear important for ANXA1 functions; 
SUMOylation may interfere with the inward vesiculation process of MVBs and 
thus late events in EGFR trafficking [261]. A structural analysis of ANXA1 
revealed that Lys257 is located in a hot spot where Ca2+ and Small Ubiquitin-
related MOdifier-1 (SUMO-1) bind and where a nuclear export signal and a 
polyubiquitination site are also present. Also, Tyr21 is buried inside an α-helix 
structure in the Ca2+-free conformation implying that Ca2+ binding and the 
subsequent expelling of the N-terminal α-helix in a disordered conformation, 
is permissive for its phosphorylation. So SUMOylation can be regulated by an 
external signal (EGF) and can indicate the presence of a cross-talk between 
the N-terminal and C-terminal domains of ANXA1 through post-translational 
modifications [262]. 
Generally, phosphorylation, much more than other kinds of 
modifications, induced the N-terminal peptide cleavage by a number of 
proteases, including elastase, calpain, plasmin, cathepsin D and proteinase 3 
[264; 265; 266; 267]. The N-terminal truncated ANXA1 is known to be capable 
to mediate lots of protein functions such as proinflammatory effects and 
promotion of neutrophil transendothelial migration [268]. In their work, 
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Rescher et al, hypothesize that the neutrophils produce elastase to create a 
compensatory mechanism between the inflammatory reaction and the anti-
inflammatory effects of ANXA1 [265]. 
 
4.5 ANXA1 in cancer 
ANXA1 performs multiple functions in tumors. Lots of experimental 
data about characterization of ANXA1 expression and localization show that 
the role of this protein can change according to the different cancer models 
[269]. 
4.5.1 ANXA1 in prostate cancer 
In human prostate adenocarcinoma, particularly in androgen-
stimulated prostate cancer, ANXA1 is decreased if compared to benign 
prostate epithelium; the loss of protein expression is an useful indicator for 
cancer proliferation and progression and a potential parameter to evaluate the 
anticancer drug resistance. ANXA1 negatively mediates IL-6 expression and 
play a proapoptotic role by mediating p38 and JNK [270; 271; 272; 273; 274; 
275]. In vitro, ANXA1 expression reduced tumourigenicity and cell viability in 
prostate cancer cell lines by enhancing activation of pro-apoptotic signaling 
pathways [276]. The inverse expression of CK18 and ANXA1 has been well 
characterized also in prostate cancer cells: luminal cells, with epithelial 
phenotype present poor level of ANXA1, instead the basal cells (expressing 
CK5) has high level of this protein. Furthermore it has been reported that 
ANXA1 from prostate-derived cancer-associated fibroblasts (CAF) is capable 
of inducing EMT, promoting de novo generation of cancer stem cells (CSCs) 
and stimulating the CSC population from prostate cancer cells [277]. Another 
important event during the EMT and prostate tumor progression is the break 
in the dynamic dialog between ANXA1 and cytokeratin 18 (CK18), a 
cytoskeleton protein, considered as one the most important epithelial 
markers. In normal breast tissue but also in benign lesion or breast 
carcinoma, the difference in the expression between ANXA1 and CK18 is not 
significant. During the EMT, in luminal cells becoming mesenchymal ones, 
CK18 is lost, on the other hand, ANXA1 expression increases, in this way, 
ANXA1 cannot co-localize with CK18/CK8, a protein complex involved in the 
cytoskeleton organization. A very similar situation appears in the prostate 
cancer where the ANXA1 has been studied in the acquisition of a more 
aggressive phenotype: the more invasive prostate cancer cells show not only 
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EMT but also CSCs markers and express an increased level of ANXA1. 
When the ANXA1 expression decreases, the invasive and migratory capability 
of these cells falls down together with all the detected markers for EMT and 
CSCs (like NANOG, Oct-4, ALDH7A1, CD44 and CD133 as well as Snail and 
Sox2), beyond to other genes involved in the acquisition of chemoresistance 
as ABCG2 [278].  
 
4.5.2 ANXA1 in colon rectal cancer  
In colon rectal cancer (CRC) ANXA1 promotes progression, invasion 
and metastasis, as demonstrated by in vitro and in vivo systems and 
positively correlates with K-ras gene mutations in tumorigenesis. The protein 
stimulates CRC cell migration through activating the FPR [279; 280; 281; 282; 
283].  
 
4.5.3 ANXA1 in lung cancer 
ANXA1 is up-regulated in A549-LAC and H446-SCLC lung cancer 
cells and patients’ tissues; ANXA1 is associated with progression, metastasis, 
drug resistance and differentiation of this cancer [284; 285; 286]. In a study 
about lung cancer, the authors reported that the expression of ANXA1, A2 
and A3 closely related to cisplatin resistance and an up-regulation in cisplatin 
resistant patients’ tissues appears both in mRNA and protein levels [287]. 
 
4.5.4 ANXA1 in melanoma 
A very well characterized model in which ANXA1 has been studied is 
melanoma. The protein is up-regulated in metastatic B16 mouse cells and 
subsequent syngeneic primary tumors when compared with non-metastatic 
B16F10 cells. ANXA1 promotes the invasion and metastasis of melanoma 
through its interaction with the FPRs [288; 289; 290].  
 
4.5.5 ANXA1 in breast cancer 
In breast cancer (BC), ANXA1 can play a paradoxical role. The protein 
is down-modulated in estrogen-resistant cells, compared with the non-
malignant ones. ANXA1 might act as a stress protein protecting cells from 
heat- and estrogen-induced growth arrest, DNA damage and proliferation in 
MCF-7 cells, possibly through enhanced ERK activation and inhibited JNK 
activation [291; 292]. ANXA1 knockdown by siRNA attenuates proliferations 
of MCF-7 and MDA-MB-231, suggesting a mitogen function through FPR 
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activation [293; 294]. It is reported that ANXA1 may act as an EMT/metastasis 
suppressor for BC: RNAi-mediated ANXA1 knockdown induced EMT and 
metastasis in nonmetastatic cells. Strikingly, restored Anxa1 expression 
reversed EMT and abolished the metastasis of BC [295]. Therefore, ANXA1 
negatively regulates the proliferation of breast epithelial cells and contributes 
to maintaining normal breast biology. Furthermore, ANXA1 expression is 
associated with a highly invasive basal-like BC subtype. Its knockdown in 
invasive basal-like BC cells reduces the number of spontaneous lung 
metastasis, whereas its re-expression enhanced the cell’s metastatic 
capacity. ANXA1 promotes the metastasis by enhancing TGF-β/Smad 
signaling and actin reorganization, which facilitates an EMT-like switch, 
thereby allowing efficient cell migration and invasion of metastatic BC cells 
[296]. ANXA1 could be utilized as an additional marker to better discriminate 
basal-like BC from other subtypes, with an inverse correlation with 
cytocheratin 18, marker of luminal cell, in fact ANXA1 appears much more in 
mioepithelial cells compared with epithelial ones [297; 298]. ANXA1 
knockdown inhibits the migration and invasion of MDA-MB-231. 
Consequently, ANXA1 down-regulation decreases MMP-9 mRNA and protein 
levels, as well as its activity, which further suppresses the activity of NF-kB 
[299]. All these information suggest that ANXA1 can perform a double role in 
BC development, functioning as oncogene and oncosuppressor. In addition, 
ANXA1 -/- mice showed a particular reduction of the known EMT markers like 
vimentin, as well as myosin light-chain kinase which has been reported to 
induce Rho-kinase mediated assembly to stress fibers known to be implicated 
in the EMT [300]. 
4.5.6 ANXA1 in pancreatic cancer 
ANXA1 is over-expressed in PDAC tissues and up-regulated 1.7-fold 
in TS-1-resistant cells; ANXA1 correlates with poor differentiation, prognosis 
and drug resistance of PC [301; 302; 303]. 
 
4.6 ANXA1 externalization  
Secreted eukaryotic proteins use an N-terminal signal peptide to direct 
their co-translation on Endoplasmic Reticulum (ER)-bound ribosomes into the 
ER lumen, after which they progress to the Golgi apparatus and are ultimately 
exported through secretory vesicles to the cell surface or to the extracellular 
environment [304]. ANXA1 sequence analysis revealed the lack of an N-
terminal signal peptide, required for classical externalization of the protein, 
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suggesting that ANXA1 could be externalized through non-classical secretory 
pathways [305]. Furthermore, it has been often observed that following its 
externalization, ANXA1 undergoes a proteolytic cleavage on its N-terminal 
end [306; 265; 292]. Different studies aimed to characterize ANXA1 
externalization process and it appears that the protein could be externalized 
through five mechanisms.  
 ANXA1 externalization depends on a myristoylation process, since 
sequence of ANXA1 includes potential sites for this modification and 
the PKC targets its myristoylated substrate to the plasma membrane. 
ANXA1 lipidation could be a prerequisite step for membrane targeting 
and a process facilitatin the protein passage across the plasma 
membrane [307]. 
 The ATP-Binding Cassette (ABC)-A1 is a transporter involved in 
ANXA1 secretion even if the authors found that its inhibition does not 
completely abrogate ANXA1 externalization, suggesting that other 
non-classical mechanisms might contribute to protein release [308]. 
 In PMNs, upon adhesion to endothelial cells, granules translocate and 
fuse with the plasma membrane, during a process called 
degranulation, leading to release of ANXA1 in the extracellular 
compartment [309]. 
 Following the activation of flippases and scramblases, the bud-lipid 
bilayer becomes inside-out orientated with phosphatidylserine being 
exposed to the outside. Since ANXA1 has a great affinity for acidic 
phospholipids, the hypothesis of microparticles surface associated 
ANXA1 is addressed [310].  
 After the fusion process of exosomes, small endosome-derived 
vesicles, ranging in size from 40 to 100 nm in diameter, with the 
bilayer membrane, all the proteins associated with them could be 
externalized; among them it has been recognized ANXA1 [311].  
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CHAPTER 5  
 
Formyl Peptide Receptors 
 
5.1 Introduction 
Studies conducted throughout the 1980s led to the identification of the 
Formyl Peptide Receptors (FPR) as a little class of trans-membrane seven 
domains receptors, coupled to G protein (GPCR) (Fig. 5.1); they are known to 
be important in several mechanisms for immune defense and discovered for 
the first time in mammalian leucocytes [312]. 
The FPR gene family has a complex evolutionary history. The principal 
ligands for FPRs are bacterial and mitochondrial formylated peptides, actively 
secreted by invading pathogens or passively released from dead and dying 
host cells after tissue injury. The binding of the N-formyl methionine motifs of 
bacterial and mitochondrial-derived peptides to FPRs was initially described 
over 3 decades ago and was the starting point for the subsequent dissection 
of the many G-protein signaling within neutrophils. All major neutrophil 
functions stimulated by fMLP (fMet-Leu-Phe) can be inhibited by treatment of 
the cells with pertussis toxin [313].  
Using low-stringency hybridization with FPR cDNA as the probe, two 
separate but relatively conserved low-affinity receptors, initially termed FPR-
like 1 (FPRL1) and FPR-like 2 (FPRL2), were cloned from an mRNA of 
neutrophil-like promyelocytic HL-60 cells. These receptors have been 
renamed FPR2/ALX and FPR3, respectively, as more has become known 
about their distinct biochemical and physiological roles. All three receptors are 
clustered together on chromosome 19q13.3 and share significant sequence 
homology. FPR1 has 69% amino acid identity with FPR2 and 56% with FPR3, 
whereas FPR2 and FPR3 share 83% identity. Despite the relatively high level 
of sequence homology, FPR2/ALX is a low-affinity receptor for fMLF, with a 
Kd of 430 nM [314; 315]. Subsequent studies demonstrated that the 
recombinant FPR1 is able to mediate fMLF-induced actin polymerization and 
chemotaxis in transfected HL-60 cells [316]. 
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Figure 5.1: Structure of the FPR1 receptor and key polymorphisms within the protein. 
(green), polymorphisms associated with disease states including juvenile and 
aggressive periodontitis (red), hypertension in young adults (orange), gastric cancer 
(pink; denotes D192K) and those that have been observed but whose functional 
significance remains uncertain (blue) [317]. 
 
 
Unlike FPR1 and FPR2/ALX, FPR3 transcripts are not found in 
neutrophils. Instead, it can be detected together with transcripts for FPR1 and 
FPR2/ALX in monocytes, although the expression pattern changes with 
monocyte differentiation. In particular, in the process of monocyte 
differentiation into immature dendritic cells (DC), the cellular expression of 
FPR2/ALX progressively declines, whereas FPR2/ALX expression remains 
unchanged during monocyte differentiation into macrophages. There is a 
progressive loss of FPR1 during differentiation of immature DC to mature DC, 
such that FPR3 becomes the predominant human FPR in mature DC. The 
biological significance of differential expression of FPRs in monocytes, 
macrophages, and DCs has not yet been clearly delineated [318; 319]. 
 
5.2 FPR mechanism of action 
5.2.1 FPR1 
As shown in figure 5.2, after binding of ligand to FPR1, conversion of 
guanosine diphosphate (GDP) to guanosine triphosphate (GTP) induces 
dissociation of the α from the βγ subunits, activating phospholipase C β 
(PLCβ). Hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) by PLCβ 
generates inositol 1,4,5-trisphosphate (IP3), which releases calcium from 
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endoplasmic reticulum stores activating calmodulin (CaM)/calcineurin 
pathway, and DAG, which activates PKC isoforms. PKC is also able to induce 
NF-kB translocation to the nucleus. The G protein βγ subunit recruits 
phosphoinositide-3 kinase (PI3K) to the plasma membrane, thereby 
enhancing the activity of Src-like tyrosine kinases, which phosphorylate 
docking proteins such as the Shc adaptor proteins. A functional association 
between Shc, Grb2 and Sos follows, leading to the activation of the Ras-Raf-
MEK-ERK pathway and therefore transcriptional regulation. ERK1/2 play also 
a role in FPR-mediated oxidant production: these kinases are known to 
catalyze the phosphorylation of p47phox prompting membrane translocation 
of cytosolic factors. Assembly of a membrane complex of NADPH oxidase is 
key to its conversion of molecular oxygen to superoxide. The stimulation of 
FPR receptors leads also to the activation of low molecular weight G proteins 
of the Rho family (Rho, Rac and Cdc42 -Cell division control protein 42-), via 
the activation of guanine-nucleotide exchange factors (GEFs) such as Vav1 
or pRex1. The Rho GTPases are key regulators of many functions, including 
cell adhesion, chemotaxis and superoxide generation. Rac and Cdc42 are 
involved in the remodeling of the actin cytoskeleton at the leading edge of 
migrating cells. The activation of Cdc42 is thought to release the auto-
inhibited conformation of the Wiskott–Aldrich syndrome protein (WASP), a 
multi-domain protein that is an activator of the nucleating Arp2/3 complex. 
Concluding, the activation of FPR triggers a range of intracellular kinase 
pathways, resulting in the induction of a variety of cell functions, including 
neutrophil chemotaxis, degranulation, superoxide anion production and 
activity; the predominant signaling pathways are those of PI3K, mitogen-
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Binding of serum amyloid A or the cathelicidin-associated antimicrobial 
peptide leucine-leucine-37 (LL37) to FPR2/ALX results in proinflammatory 
responses with neutrophil NF-kB activation and cytokine release, increased 
neutrophil recruitment to sites of inflammation and increased neutrophil 
lifespan. In contrast, binding of ANXA1 inhibits neutrophil migration, promotes 
neutrophil apoptosis, increases the rate of macrophage phagocytosis of 
apoptotic cells and skews the macrophages toward a less proinflammatory 
phenotype. These effects elicited from ligand binding to the same receptor 
have recently been attributed to different dimerization states after agonist 
binding that alter receptor conformation and subsequent intracellular signaling 
[322; 323; 324]. 
 
5.2.3 FPR3 
Distinct from the other members of the FPR family, the function of 
FPR3 remains relatively poorly understood. While not expressed on human 
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neutrophils, it is found in eosinophils, monocytes, macrophages, and DCs, 
leading to speculation that it may play a role in the pathogenesis of allergic 
disease. FPR3 is relatively insensitive to formylated peptides and few specific 
endogenous ligands have been identified. F2L, an endogenous 21 amino acid 
acetylated amino-terminal peptide, is the most specific ligand described to 
date [325; 326]. Derived from cleavage of heme binding protein 1 by 
cathepsin D, F2L activates FPR3 in low nanomolar concentrations. In doing 
so, it induces monocyte intracellular calcium flux, ERK1/2 phosphorylation 
and chemotaxis while also augmenting LPS-mediated IL-12 production in 
DCs, thereby inhibiting their maturation. Humanin, a neuroprotective peptide, 
also binds with high affinity to both FPR2 and FPR3 [327; 321]. Despite the 
high sequence homology with FPR2/ALX, the behavior of FPR3 is surprising, 
with significantly higher basal levels of receptor phosphorylation and 
internalization and relative insensitivity to common FPR2/ALX ligands. This 
observation has led to the hypothesis that it may also act as a decoy receptor 
to bind extracellular ligands, thereby regulating the function of other 
formylated peptide receptors. Although there is likely to be some functional 
overlap with FPR2/ALX, the true functional role of FPR3 and its relevance in 
vivo remain to be determined [328]. 
 
 
5.3 Ligands of FPR family 
 
5.3.1 Agonists 
With the exception of the eicosanoid LXA4, all the ligands of FPRs are 
peptides and, recently, it has been possible to add to the list of formyl 
peptides, also the low molecular weight synthetic compounds which derive 
from proteins libraries. The yet cited fMLP acts with its own amino acidic 
residues in different three receptor tasks, the formyl group and the carbonyl 
one of the phenylalanine are important for the bind between two molecules 
[313].  
Beyond the N-formylpeptides, a large number of endogen peptides, 
also not formylated ones, has been identified as agonists, above all for the 
FPR2/ALX. Serum amyloid A (SAA) protein is an acute-phase protein the 
serum concentration of which is increased in response to trauma, acute 
infection and other environmental stress causing acute-phase responses; it 
has been the first endogen agonist identified in the mammalian organisms. 
Interacting with FPR2/ALX, it functions as chemotactic factor for monocytes, 
neutrophils, mast cells and T lymphocytes; stimulates production of 
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metalloproteases and cytokines and increases expression of cytokine 
receptors [329; 330].  
The 42-amino acid form of β amyloid peptide which is a cleavage 
product of the amyloid precursor protein in the brain and a pathologic protein 
in Alzheimer’s disease (Aβ42), was also found to activate FPR2/ALX. It 
provokes migration and activation of monocytes and microglia, as shown by 
the increased flux of Ca2+ which enhances its own endocytosis [331; 332].  
A cecropin-like peptide from Helicobacter pylori, Hp(2–20), was found 
to attract monocytes and basophils to the gastric mucosa in response to 
bacterial infection. Hp(2–20) was identified as an agonist at FPR2/ALX and 
FPR3. Despite the absence of an N-formyl group in this case, Hp(2–20) is a 
full agonist capable of stimulating superoxide production [333; 334]. 
In addition to HIV-1 proteins, other viral proteins contain sequences 
that can serve as ligands for FPRs when tested in the form of synthetic 
peptides. In Herpes simplex virus type 2, a gG-2p20 peptide corresponding to 
amino acids 190 to 205 of the secreted glycoprotein sgG-2 activates 
neutrophils and monocytes via FPR1. The gG-2p20–induced activation of 
phagocytes releases ROS that inhibits NK cell cytotoxicity and accelerates 
apoptotic cell death [335; 336]. 
LL-37, an enzymatic cleavage fragment of the neutrophil granule 
protein cathelicidin and its mouse homolog CRAMP are agonists for 
FPR2/ALX. LL-37 is expressed by leukocytes and epithelial cells and 
secreted into wounds and onto the airway surface. In addition to its 
microbicidal activity, LL-37 induces directional migration of human monocytes, 
neutrophils and T lymphocytes, a function mediated by FPR2/ALX. Other 
studies showed that LL-37-induced angiogenesis is mediated by FPR2/ALX in 
vascular endothelial cells. Decreased vascularization during wound repair 
observed in mice deficient for CRAMP indicates that cathelicidin-mediated 
angiogenesis is important for cutaneous wound neovascularization in vivo. 
LL-37 seems to be a multifunctional peptide with a central role in innate 
immunity against bacterial infection and in the induction of arteriogenesis 
important for angiogenesis [337; 338]. 
In 2005, it has been identified F2L as agonist of FPR3. It is a peptide 
with the acetylated N-terminal portion, deriving from a natural protein 
cleavage capable to bind the eme group. This molecule enhances the 
migration of immature DCs and monocytes also at low concentrations [339]. 
LXA4 (5S,6R,15S-trihydroxy-7,9,13-trans-11-eicosatetraenoic acid) is 
a potent mediator biosynthesized from arachidonic acid. It is a small molecule 
with physical chemical properties that displays multilevel control of processes 
relevant in acute inflammation via specific and selective actions on multiple 
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cell types via specific receptors. In particular, LXA4 has been reported to 
interact directly with both human FPR2/ALX and CysLT1 (Cysteinyl 
leukotriene receptor 1). It also induces signals that regulate production of 
chemokines, cytokines (for example TNF) and growth factor receptors (as 
VEGFR) in human leukocytes, vascular cell types and mucosal epithelial 
cells, each contributing to regulate the resolution of inflammation [340; 341].  
As previously described, ANXA1 is an important agonist of FPRs, 
particularly it has been a major affinity of the ANXA1 full length on FPR1 and 
of its N-terminal peptide Ac2-26 on FPR2. Besides all the reported information 
about the anti-inflammatory effects of ANXA1 on FPRs, focusing for example 
on the capability of ANXA1 to promote intestinal epithelial migration through 
activation of FPR1-, Rac1- and NOX1-dependent redox signaling, it has been 
investigated also the importance of Ac2-26 and FPR2 in atherogenesis and 
identified a prominent protective effect [342; 343; 344]. Furthermore ANXA1 
can promote skeletal muscle cell and skin fibroblasts migration by acting 
through FPRs [345; 346]. Recently, several studies have been published 
about the role of the interaction of ANXA1 and FPRs in cancer [347; 294; 283] 
 
5.3.2 Antagonists  
Biochemical studies reported that replacing the formyl group of fMLP 
with tertiary butyloxycarbonyl group (t-Boc) it is possible to obtain an 
antagonist effect; the most used compounds are Boc1 (t-Boc-Met-Leu-Phe) 
and Boc2 (t-Boc-Met-D-Leu-D-Phe). If it is utilized at high concentration 
(100µM), Boc2 inhibits FPR2/ALX, instead at lower concentration (nM), both 
Boc1 and Boc2 act as antagonists of FPR1, finally, at a quantity that is higher 
than micromolar Boc2 blocks both FPR2/ALX and FPR1. Moreover, Boc2 is 
less selective at elevated quantity, differently from WRW-WWW (Trp-Arg-Trp-
Trp-Trp-Trp-CONH2) which inhibits selectively FPR2/ALX also at high doses. 
This peptide inhibits the augmentation of intracellular Ca2+  and the 
consecutive neutrophil migration and ROS formation induced by Aβ42 [348; 
349].  
Cyclosporin H (CsH) is a cyclic undecapeptide produced by fungi with 
an effect of selective inverse agonist on FPR1, with a greater power than 
Boc1 and Boc2. It has not immunogenic activities, in fact, its capability to 
inhibit the neutrophil activation and the O2
- formation, induced by fMLP, and 
the chemotactic effect on leucocytes is due exclusively to its interaction with 
FPR1 [350].  
Some agonist and antagonist compounds and their structure are 
summarized in table 5.1.  
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Table 5.1: Chemical structure of selected ligands for the FPRs [313]. 
 
 
5.4 Regulation of FPRs 
After a prolonged stimulation by fMLP, the cell response is reduced 
and cells begin to appear resistant to administration of other agonists. This 
phenomenon could be explicated through the homologous or heterologous 
desensitization. In the first case, the GPCR FPR is phosphorylated in its Ser 
and/or Thr residues by a G protein coupled kinase (GRK); the 
phosphorylation sites become as recognition and binding ones for the β-
arrestin with which the receptor, probably, is internalized. In the second case, 
instead, it is hypothesized that the interaction with the ligand triggers some 
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5.5 FPRs in cancer 
Besides their involvement in inflammatory disorders, FPRs have been 
implicated in the regulation of tissue repair and angiogenesis; the evidence for 
their central role at the intersection between inflammation, physiologic 
angiogenesis and pathologic neovascularisation links the receptors to cancer 
[352]. On one hand FPRs participate in intestinal, lung and retinal pigment 
epithelial cell restitution but, on the other hand, the role in cancer seems to be 
context-specific [353; 354; 355]. Recently, FPR1 has been shown to be 
expressed by highly malignant glioblastoma cells. Upon activation by ANXA1, 
released by necrotic glioma cells, FPR1 transactivates EGFR and 
consequently promotes glioma cell chemotaxis, invasion, growth and 
production of angiogenic factors. Depletion of FPR1 markedly reduced the 
malignancy of glioma cells both in vitro and in vivo [356; 357; 358]. By 
contrast, in a mouse colon carcinogenesis model, FPR2 knockout in 
epithelial, but not in immune cells, markedly increased tumor formation and a 
positive association between a specific FPR1 polymorphism and gastric 
cancer has recently been described, particularly the stimulation of FPR1, 
FPR2 and FPR3 induces the EMT, cell proliferation, survival and 
invasiveness of gastric cancer cells [359; 360; 361; 362]. 
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PC has a poor prognosis, even if diagnosed early. It typically spreads 
rapidly and its detection appears very difficult in early stages; signs and 
symptoms may not appear until PC is quite advanced and complete surgical 
removal is not sufficient. These reasons are the major ones why PC is a 
leading cause of cancer death.  
Beyond the anti-inflammatory function, ANXA1 may also play a tumor 
suppressor or enhancer role depending on the type of tissue and organ. 
During PC progression, ANXA1 is found over-expressed as shown by 
immunohistochemical analysis or multi tissue array studies, both of them 
carried out on patients’ biopsies. The increase of its expression correlates 
with the most advanced stages of tumor, nevertheless a specific role for 
ANXA1 in this cancer has not been yet defined. Therefore, this work presents 
as principal aim the investigation of the role of ANXA1 in human PC. The in 
vitro initial approach, based on the use of immortalized cell lines, allowed to 
focus the attention on several aspects of tumor development, such as 
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CHAPTER 6  
 
MATERIAL AND METHODS 
 
6.1 Cell Cultures 
MIA PaCa-2, human PC cells, were cultured in DMEM (Lonza) 
containing L-Glutamine 2 mM, 10% heat-inactivated fetal bovine serum (FBS; 
Lonza) and 2,5% heat inactivated horse serum (HS; Lonza). PANC-1, human 
pancreatic epithelioid carcinoma cells, were kept in DMEM containing L-
Glutamine 2 mM and 10% heat-inactivated fetal bovine serum (FBS; Lonza). 
BxPC-3, human pancreatic adenocarcinoma cells, were cultured in RPMI 
1640 (Lonza) containing 10% heat-inactivated fetal bovine serum (FBS; 
Lonza). CAPAN-2, human PDAC cells, were kept in McCoy's 5a Medium 
Modified (Lonza) with 10% heat-inactivated fetal bovine serum (FBS; Lonza). 
All the media were supplemented with antibiotics (10000 U/ml penicillin and 
10 mg/ml streptomycin; Lonza). Cell lines were purchased from ATCC 
(Rockville, USA) and were stained at 37°C in 5% CO2 -95% air humidified 
atmosphere. 
 
6.2 Cytosol and membrane extracts 
MIA PaCa-2 and PANC-1 cells were washed twice with PBS, 
detached with trypsin-EDTA 1x in PBS (Euroclone), harvested in PBS and 
centrifuged for 5 minutes at 600 x g at 4°C. After that, the pellets were 
resuspended in 4 ml of lysis buffer (Tris HCl 20 mM, pH 7,4; sucrose 250 mM; 
DTT 1 mM; protease inhibitors, EDTA 1 mM in water), sonicated (5 seconds 
pulse - 9 seconds pause for 2 minutes, amplitude 42%) and then centrifuged 
at 4°C for 10 minutes, at 5000 x g. The obtained supernatants were ultra-
centrifuged for 1 hour at 100000 x g at 4°C, until to get new supernatants that 
represent cytosol extracts. Each resulting pellet was resuspended in 4 ml of 
lysis buffer and ultra-centrifuged for 1 hour at 100000 x g at 4°C. The pellets 
were then resuspended in 250 µl of solubilization buffer (Tris HCl 20 mM, pH 
7,4; DTT 1 mM; EDTA 1 mM; Triton X-100 1%, in water) and left overnight on 
orbital shaker at 4°C. After that, the solution was centrifuged for 30 minutes at 
50000 x g at 4°C: the supernatants represent membrane extracts. To detect 
membrane expression of ANXA1 we also use an EDTA Wash method: cells, 
kept on ice, were washed twice with PBS and then with a buffer 5 mM EDTA 
and protease inhibitors for 10 minutes. 
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6.3 Nuclear extracts 
MIA PaCa-2 and PANC-1 cells were washed twice with PBS, 
detached with trypsin-EDTA 1x in PBS (Euroclone), harvested in PBS and 
centrifuged for 5 minutes at 600 x g at 4°C. The pellets were resuspended in 
500 µl of buffer A (Hepes pH 7.9 10 mM, EDTA pH 8.0 1 mM, KCl 60 mM, N-
P40 0.2%, DTT 1 mM, PMSF 1 mM, protease inhibitors) and then left on ice 
for 10 minutes. After that, the samples were centrifuged at 660 x g for 5 
minutes at 4°C, resuspended in 50 µl of buffer B (Tris HCl pH 7.8 250 mM, 
KCl 60 mM, DTT 1 mM, PMSF 2 mM, glycerol 20% v/v in PBS) and 
centrifuged again at 9500 x g for 15 minutes at 4°C. The obtained pellets 
were resuspended in 100 µl of buffer C (Hepes pH 7.9 10 mM, EDTA pH 8.0 
1 mM, KCl 60 mM, DTT 1 mM, PMSF 1 mM, protease inhibitors) and 
centrifuged at 660 x g for 5 minutes at 4°C. The samples were then washed 
twice with 1 ml of buffer C, resuspended in 50 µl of buffer B and exposed to 3 
cycles of freeze/thawing. Finally, the samples were centrifuged at 9500 x g for 
15 minutes at 4°C: the pellets represent the nuclear extracts. 
 
6.4 Supernatant analysis 
Cell growth media were harvested, frozen at -80°C and lyophilized. 
Dried samples were suspended in lysis buffer containing protease inhibitors 
and left at 4°C for 30 minutes. After centrifugation, the supernatants were 
filtered through Amicon Ultra-15, PLTK Ultracel-PL Membrane, 10 kDa 
(Millipore). The filtrates were loaded on a Chromabond HR-X micro-column 
(Macherey-Nagel) and eluted with 70% ACN and 95 % ACN. Eluted samples 
were analyzed by LC/MS/MS using an Orbitrap XL instrument (Thermo 
Scientific) as reported elsewhere [363]. 
 
6.5 Western blotting analysis  
Expression of ANXA1 was examined by SDS-PAGE. Total intracellular 
proteins were extracted from the cells by freeze/thawing in lysis buffer 
containing protease inhibitors. Protein content was estimated according to 
Biorad protein assay (BIO-RAD). Samples (20 µg protein) were loaded onto 
10% denaturing-polyacrylamide gel and separated by SDS-PAGE. The 
separated proteins were then transferred electrophoretically to nitrocellulose 
membranes (Immobilon-NC, Millipore). Membranes were blocked with 5% 
non-fat dry milk in TBS-Tween 20 (0.1% v/v) and then incubated overnight at 
4°C with the primary antibodies. Proteins were visualized using the enhanced 
chemioluminescence detection system (Amersham Pharmacia Biotech) after 
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incubation overnight at 4 °C with primary polyclonal antibodies against 
ANXA1 (1:10000; Invitrogen), ERK and p-ERK (1:1000; Cells Signaling), CK 8 
(1:1000; Abcam) monoclonal ones against vimentin (1:1000; Santa Cruz 
Biotechnologies), cyclin A (1:1000; Santa Cruz Biotechnologies), ALDH7A1 
(1:1000; Abcam), α-tubulin (1:1000; Sigma-Aldrich) and GAPDH (1:1000 
Santa Cruz Biotechnologies) and then at room temperature with an 
appropriate secondary rabbit or mouse antibody (1:5000; Sigma-Aldrich). 
Immunoreactive protein bands were detected by chemioluminescence using 
enhanced chemioluminescence reagents (ECL; Amersham), the blots were 
exposed and analyzed to Las4000 (GE Healthcare Life Sciences). 
 
6.6 siRNA transfection 
The 4, 6, 7 and 8 siRNA sequences against ANXA1 were purchased 
from Qiagen and used at a final concentration of 5 nM. siRNA Oligo-
Scrambled (Santa Cruz Biotechnology) was used as control at the same 
concentration. siRNAs were transfected using Lipofectamine 2000 Reagent 
(Life technologies Corporation), according to the manufacturer’s instructions. 
Cells were harvested after 72 hours from transfection.  
 
6.7 Confocal Microscopy 
After the specific time of incubation, MIA PaCa-2, PANC-1, BxPC-3 
and CAPAN-2 cells were fixed in p-formaldehyde (4% v/v in PBS) for 5 
minutes. The cells were permeabilized in Triton X-100 (0.5% v/v in PBS) for 5 
minutes, and then incubated in goat serum (20% v/v PBS) for 30 minutes, and 
with rabbit anti-ANXA1 antibody (1:100; Invitrogen), mouse anti-FAK (1:100; 
BD Transduction Laboratories), mouse anti-E-cadherin (1:250; Abcam), 
mouse anti-vimentin (1:500; Abcam), mouse anti-lamin A/C (1:450; 
Novocastra) overnight at 4°C. After two washing steps with PBS, cells were 
incubated with anti-rabbit and / or anti-mouse AlexaFluor (488 and/or 555; 
1:1000; Molecular Probes) for 2 hours at RT and then with FITC-conjugated 
anti-F-actin (5µg / ml; Phalloidin-FITC, Sigma) for 30 minutes at RT in the 
dark. The coverslips were mounted in glycerol (40% v/v PBS). A Zeiss LSM 
710 Laser Scanning Microscope (Carl Zeiss MicroImaging GmbH) was used 
for data acquisition. To detect nucleus, samples were excited with a 458 nm 
Ar laser. A 555 nm He-Ne laser was used to detect emission signals from 
ANXA1 stain. Samples were vertically scanned from the bottom of the 
coverslip with a total depth of 5 mm and a 63X (1.40 NA) Plan-Apochromat 
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oil-immersion objective. Images were generated with Zeiss ZEN Confocal 
Software (Carl Zeiss MicroImaging GmbH). 
 
6.8 Flow cytometry  
MIA PaCa-2 and PANC-1 cells were harvested at a number of 1 x 106 
and centrifuged at 30000 x g for 5 minutes. The pellets were then incubated 
on ice for 1 hour in 100 µl of PBS containing a primary polyclonal antibody 
against FPR-1 (1:500, Santa Cruz Biotechnology) or a primary monoclonal 
antibody against FPR-2 (1:100, Genovac). After that, MIA PaCa-2 and PANC-
1 cells were washed twice and incubated on ice for 1 hour in 100 µl of PBS 
containing AlexaFluor 488 anti-rabbit (1:1000; Molecular Probes) or Alexa-
Fluor 488 anti-mouse (1:1000; Molecular Probes). About the expression of 
CD44, cells were incubated on ice for 30 min in 100 µl of PBS containing 
APC-conjugated CD44 anti-human antibody, APC-conjugated human IgG1 
was used as scrambled. The cells were analyzed with Becton Dickinson 
FACScan flow cytometer using the Cells Quest program. 
 
6.9 PCR 
MIA PaCa-2 and PANC-1 cells were seeded at an initial density of 1 x 
106 in a 100 mm Petri dish and incubated for 48 hours in growth medium 
allowing cells to reach 90% confluency. Total RNA was extracted from cells 
using Trizol (Invitrogen) [24]. Total RNA (5 µg) was used to synthesize cDNA 
using a reverse transcription kit (Roche). PCR was conducted by using the 
following primers: 
FPR-1 primer pair: (fwd 5’-CAA GAT GGA GAC AAA TTC CTC TC-3’) 
and (rev 3’-GAG CAG AGC CAT CAC CCA GGG CCC AA-5’);  
FPR-2 primer pair: (fwd 5’-CTG TAC TTT CAA CTT TGC ATC C-3’) 
and (rev 3’-ATT TCC CAA CTC CAC TTA CC-5’);  
The predicted FPR-1 and FPR-2 products are 469 bp and 773 bp 
respectively. The FPR-1 and FPR-2 genes were amplified using PCR under 
the following conditions: pre-denaturation at 94°C for 2 minutes, 35 cycles of 
denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds, 
extension at 72°C for 30 seconds and a final extension at 72°C for 10 
minutes. The products were stored at 4°C. A portion (5 µl) of the PCR product 
was electrophoresed on a 1% agarose gel in a Tris-acetate-EDTA buffer. The 
gel was stained with ethidium bromide and was scanned and analysed to 
Las4000 (GE Healthcare Life Sciences). 
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6.10 RNA isolation and quantitative RT-PCR assay 
mRNA levels of MIA PaCa-2 WT, PGS and ANXA1 KO were analysed 
by Real- time PCR using the Light Cycler 480 II instrument (Roche). Total 
RNA was extracted from cultured cells using TriPure Isolation Reagent 
(Roche), 1µg of total RNA was reverse transcribed into cDNA with 
Transcriptor First Strand cDNA Synthesis Kit (Roche). 5µl of 1:10 diluted 
cDNA were used in a 20µl reaction using Light Cycler 480 Probes Master and 
Real Time Ready Catalog Assay primers (Roche) for CK18 (Forward 
AATGGGAGGCATCCAGAACGAGAA, Reverse 
TTCTTCTCCAAGTGCTCCCGGATT) and HPRT1 (Forward 
GACCAGTCAACAGGGGACAT, Reverse CCTGACCAAGGAAAGCAAAG) 
following the manufacturer instruction protocol. Results were analysedusing 
the Delta–Delta CT method. 
 
6.11 Measurement of intracellular Ca2+ signalling 
Intracellular Ca2+ concentrations [Ca2+] were measured using the 
fluorescent indicator dye Fura 2-AM, the membrane-permeant acetoxymethyl 
ester form of Fura 2, as previously described [364]. Briefly, MIA PaCa-2 and 
PANC-1 cells (5 × 103/multiwell 24 culture dishes) were washed in PBS and 
re-suspended in 1 ml of Hank's balanced salt solution (HBSS) containing 5 
µM Fura 2-AM for 45 minutes. Thereafter, cells were washed with the same 
buffer to remove excess of Fura 2-AM and incubated in Ca2+-free HBSS/0.5 
mM EGTA buffer for 15 minutes to allow hydrolysis of Fura 2-AM into its 
active-dye form, Fura 2. MIA PaCa-2 and PANC-1 cells then were transferred 
to the spectrofluorimeter (Perkin-Elmer LS-55). Treatment with ionomycin (1 
µM), fMLP (50 nM, Sigma Aldrich), with Ac 2-26 (1 µM, Tocris Bioscience) or 
Boc-1 (10 µM, Bachem AG) was carried out by adding the appropriate 
concentrations of each substance into the cuvette in Ca2+-free HBSS/0.5 mM 
EGTA buffer. The excitation wavelength was alternated between 340 and 380 
nm, and emission fluorescence was recorded at 515 nm. The ratio of 
fluorescence intensity of 340/380 nm (F340/F380) was used to estimate 
intracellular free calcium. Results are indicated as delta increase of 
fluorescence ratio (F340/F380 nm) induced by ionomycin - basal fluorescence 
ratio (F340/F380 nm). 
 
6.12 In vitro wound-healing assay 
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MIA PaCa-2 and PANC-1 cells were seeded in a 12-well plastic plate 
at 5 x 105 cells per well. After 24 hours incubation, cells reached 100% 
confluency and a wound was produced at the centre of the monolayer by 
gently scraping the cells with a sterile plastic p10 pipette tip. After removing 
incubation medium and washing with PBS, cell cultures were incubated in the 
presence of fMLP (50 nM), Ac2-26 (1 µM), Boc-1 (10 µM) or in growth 
medium as control. In case of transfection with siANXA1s, cells were plated at 
a number of 2 x 105, after 24 hours were transfected with siANXA1s and with 
scrambled siRNAs and, 72 hours after transfection, wound was produced. 
The wounded cell cultures were then incubated at 37°C in a humidified and 
equilibrated (5% v/v CO2) incubation chamber of an Integrated Live Cell 
Workstation Leica AF-6000 LX. A 10x phase contrast objective was used to 
record cell movements with a frequency of acquisition of 10 minutes. The 
migration rate of individual cells was determined by measuring the distances 
covered from the initial time to the selected time-points (bar of distance tool, 
Leica ASF software). For each condition five independent experiments were 
performed. For each wound five different positions were registered, and for 
each position ten different cells were randomly selected to measure the 
migration distances. Statistical analysis were performed by using GraphPad 
Prism software (GraphPad Software Inc., version 5.0). Data are presented as 
means ± SEM. Values p<0.05 were considered as significant. 
 
6.13 Matrigel Invasion Assay 
MIA PaCa-2 and PANC-1 invasiveness was studied using the Trans-
well Cell Culture (12 mm diameter, 8.0-fim pore size) purchased form Corning 
Incorporated (USA). The chambers were coated with Matrigel (Becton 
Dickinson Labware) that was diluted with 3 volumes of DMEM serum-free and 
stored at 37°C until its gelation. Cells were plated in 350 µl of DMEM serum-
free at a number of 9 x 104/insert in the upper chamber of the trans-well. 1,4 
ml of DMEM with or without FBS were put in the lower chamber and the trans-
well was left for 24 hours at 37°C in 5% CO2 -95% air humidified atmosphere. 
After that, the medium was aspirated, the filters were washed twice with PBS 
1x and fixed with 4% p-formaldehyde for 10 minutes, then with 100% 
methanol for 20 minutes. The filters so fixed, were stained with 0,5% crystal 
violet prepared from stock crystal violet (powder, Merck Chemicals) by 
distilled water and 20% methanol for 15 minutes. After that, the filters were 
washed again in PBS 1x and cleaned with a cotton bud. The number of cells 
that had migrated to the lower surface was counted in twelve random fields 
using EVOS light microscope (10X) (Life technologies Corporation). 
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6.14 MTT assay 
MIA PaCa-2 WT, PGS and ANXA1 KO cells were seeded at 1,5 × 104 
cells/well in a 96-well plate and incubated for the indicated times (24, 48 and 
72 hours) at 37°C. At the ends of the selected experimental times, MTT stock 
solution (5 mg/ml) was added to all wells of an assay (25 μl per 100 μl 
medium), and plates were incubated at 37°C for 4 hours. At the end of each 
experimental point, cells were lysed and the dark blue crystals dissolved with 
100 μl of a solution containing 50% (v/v) N, N-dimethylformamide, 20% (w/v) 
SDS with an adjusted pH of 4.5. The optical density (OD) of each well was 
measured with a microplate spectrophotometer (Titertek Multiskan MCC/340) 
equipped with a 620 nm filter. The viability of cells was calculated as: % viable 
cells = [OD (550 nm-690 nm) ZA/OD (550 nm-690 nm) negative control] × 
100. 
6.15 Analysis of apoptosis  
The effect of gemcitabine 10µM (Sigma Aldrich) on the cell death was 
checked by propidium iodide (PI) staining and flow cytometry. Briefly, cells 
supernatant were harvested at 24, 48 or 72h from te administration of 
gemcitabine, centrifuged at 200 x g for 10 min at room temperature. The 
seeded cells were washed in PBS and resuspended in 500 µl of a solution 
containing 0.1% sodium citrate, 0.1% Triton X-100 and 50 µg/ml PI (Sigma 
Aldrich). These cells were added to the supernatant pellets and incubated at 
4°C for 30 min in the dark. Cell nuclei were analyzed with FACScan cytometer 
(Becton Dickinson) using the Cell Quest evaluation program. Cellular debris 
were excluded from the analysis by raising the forward scatter threshold and 
the DNA content of the nuclei was registered on logarithmic scale. The 
percentage of the cells in the hypodiploid region was calculated.  
 
6.16 Cell cycle analysis  
1 × 106 cells were seeded in a 6-well plate, after 24h the growth 
medium was replaced by a medium without serum to induce a chronicity 
about cell cycle. After 24h of starvation cells complemented medium was 
added again for 24, 48 and 72h. Cells were harvested and fixed in cold 70% 
ethanol at -20°C. Cell cycle profiles were evaluated by DNA staining with 2,5 
mg/ml PI in PBS supplemented with 100 U/ml ribonuclease A for 30 min at 
room temperature in the dark. Samples were analyzed with a FACScan 
cytometer (Becton Dickinson) using Cell Quest evaluation program. The 
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distribution of cells in distinct cell cycle phases was determinate using ModFit 
LT cell cycle analysis software.  
6.17 Molecular cloning by Gene/CRISPR (clustered, regularly 
interspaced, short palindromic repeat) -Cas9 (CRISPR associated 
protein 9) technique  
The CRISPR/Cas system is a powerful tool for functional screens in 
vitro and in vivo, it has been seized upon with a fervor enjoyed previously by 
small interfering RNA (siRNA) and short hairpin RNA (shRNA) technologies 
and has enormous potential for high-throughput functional genomics studies 
[365; 366]. The functions of CRISPR and CRISPR-associated (Cas) genes 
are essential in adaptive immunity in select bacteria and archaea, enabling 
the organisms to respond to and/or eliminate invading genetic material. These 
repeats were initially discovered in the 1980s in E. coli, but their function 
wasn’t confirmed until 2007 by Barrangou and colleagues, who demonstrated 
that S. thermophilus can acquire resistance against a bacteriophage by 
integrating a genome fragment of an infectious virus into its CRISPR locus 
[367; 368]. Three types of CRISPR mechanisms have been identified, of 
which type II is the most studied, in fact the simplicity of the type II CRISPR 
nuclease, with only three required components (Cas9 along with the crRNA –
CRISPR RNA- and trRNA –transactivating crRNA-) makes this system 
amenable to adaptation for genome editing. This potential was realized in 
2012 by the Doudna and Charpentier labs [369]. By now, RNA–directed Cas9 
endonuclease became a versatile tool for site-specific genome modification in 
eukaryotes; particularly, this nickase can be used to efficiently mutate genes 
without detectable damage at known off-target sites and, due to its high ease 
in building constructs, it has been widely used in humans, mice, rabbits, 
monkeys and several other species [370]. The plasmid structure is based on 
the presence of a four genes: cas9 but also cas1, cas2 and csn2, upstream 
there is the sequence for the tracrRNA as shown in figure 6.1 [371]. 
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Figure 6.1: CRISPR loci is then transcribed and processed into crRNA during crRNA 
biogenesis. During interference, Cas9 endonuclease complexed with a crRNA and 
separate tracrRNA cleaves foreign DNA containing a 20-nucleotide crRNA 
complementary sequence adjacent to the PAM sequence. 
 
 
The mechanism is based on the action of CRISPR/Cas9 which 
generates site-specific DNA double-strand breaks (DSBs) that can be 
repaired by Non-Homologous End Joining (NHEJ) pathway, resulting in 
insertions and/or deletions (indels) which disrupt the targeted locus. 
Alternatively, if a donor template with homology to the targeted locus is 
supplied, the DSB may be repaired by the homology-directed repair (HDR) 
pathway allowing for precise replacement mutations to be made [372; 373]. In 
particular, in this system, single-guide RNAs (sgRNAs) direct Cas9 nucleases 
to induce DSBs at targeted genomic regions. The 5′ end of sgRNAs includes 
a nucleotide (Fig. 6.2) sequence of around 20 nucleotides that is 
complementary to the targeted region defined as a PAM (Protospacer-
Adjacent Motif) sequence consisting of either an NGG or NAG trinucleotide 
[374; 375].  
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Figure 6.2: Genome engineering utilizing the CRISPR-Cas9 system [376]. 
 
The genome-wide CRISPR/Cas9 knockout technology shows greater 
promise compared with other loss-of-function screen techniques such as RNA 
interference (RNAi), because it is able to knockout genes at the DNA level 
and it can be considered also more efficient than more established methods, 
such as TALENs (transcription activator-like effector nucleases) or ZFNs 
(zinc-finger nucleases) [377]. However, the data generated by these screens 
pose several challenges to computational analysis. First, studies are often 
carried out with no or few replicates, which necessitates a proper statistical 
model to estimate the variance of the read counts and to evaluate the 
statistical significance of comparisons between treatment and control 
samples. Second, as different sgRNAs targeting the same gene might have 
different specificities and knockout efficiencies, a robust method is needed to 
take these factors into account in the aggregation of information from multiple 
sgRNAs. Third, depending on different screen libraries and study designs, the 
read count distributions of the CRISPR/Cas9 knockout screening experiments 
are different, as positive selection often results in a few sgRNAs dominating 
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6.17.1 Transfection of plasmid DNA and clones selection.  
AS1 ANXA1 KO plasmid and PGS scrambled plasmid were purchased 
from TwinHelix srl (Milan, srl). MIA PaCa-2 cells were transfected AS1 
ANXA1KO plasmid and with PGS scrambled vector using Lipofectamine 2000 
Reagent (Life technologies Corporation), according to the manufacturer′s 
instructions. After 48 hours from transfection, cells were replaced with fresh 
medium, and re-seeded when the cells became confluent. One week later, 
the transfected cells were subject to neomycin (G418, Euroclone spa) 
selection at concentrations of 700 μg/ml (the antibiotic dose was established 
by a previous dose-response curve starting from 200 μg/ml until to 1 mg/ml); 
the purpose was to maximize recombination and minimize the random 
insertion. When all control cells (no transfected cells) died because of the 
antibiotic, cells with plasmids, which formed several clusters in the plate, were 
harvested and replaced in 96 well plate following the method of the limit 
dilution. The wells with a single cell were selected. When it expanded, cells 
were harvested and replaced in a 12 well plate, then in larger plates. We 
performed Western blotting to test the obtained clones and only those ones 
which did not show ANXA1 were later analyzed. 
6.18 Mass spectrometry of protein extracts  
6.18.1 LC-MS/MS analysis 
Total intracellular proteins were extracted from the cells by 
freeze/thawing in lysis buffer containing protease inhibitors. Protein content 
was estimated according to Biorad protein assay (BIO-RAD). Samples (150 
µg protein) analysis was performed using a classical proteomic approach. 
Specifically, 30 µg of protein extract from each sample were resolved on a 1D 
SDS-PAGE. Resulting gel lines were cut in 10 bands, and subjected to in-gel 
digestion procedure. The gel pieces were washed with water and dehydrated 
in acetonitrile. The bands were then reduced with 25 µM DTT and alkylated 
with 50 µM iodoacetamide prior to be hydrolysed. All bands were digested 
using trypsin, by adding 30 μl of a 13 ng/μl trypsin 25 mM ammonium 
bicarbonate solution. Reaction was performed incubating the mixture 
overnight at room temperature to achieve complete digestion. The resulting 
peptide mixtures were extracted from the polyacrylamide with 50 % 
acetonitrile - 5 % formic acid, and then analysed by high resolution 
LC/MS/MS. The LC–MS system was a LTQ-Orbitrap mass spectrometer 
(Thermo Fisher Scientific Inc.) hybrid mass spectrometer system. The HPLC 
column was a Dionex 15 cm × 75 μm internal diameter Acclaim Pepmap C18, 
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2 μm, 100 Å reverse phase capillary chromatography column. The extracts (5 
μl) were injected into the column and the peptides eluted by an 
acetonitrile/0.1 % formic acid gradient at a flow rate of 0.25 μl/min were 
introduced into the source of the mass spectrometer on-line. The 
microelectrospray ion source is operated at 2.5 kV. The digest was analyzed 
using the data dependent multitask capability of the instrument, acquiring full 
scan mass spectra to determine peptide molecular weights and product ion 
spectra to determine amino acid sequence in successive instrument scans. 
6.18.2 Data analysis 
All MS/MS samples were analyzed using MaxQant software. MS/MS 
peak lists generated by the mass spectrometer were searched against the 
Human UniProtKB/SwissProt protein sequence complete proteome database. 
Searches were performed selecting alkylation of cysteine by 
carbamidomethylation as fixed modification, and oxidation of methionine and 
N-terminal acetylation as variable modifications. Mass tolerance was set to 5 
ppm and 0.6 Da for parent and fragment ions, respectively. The false 
discovery rate for both peptides and proteins were set at 0.01. “High-scoring” 
corresponded to proteins that were above the significant threshold in 
MaxQuant searches (5 % probability of false match for each proteins above 
this score). 
 
6.18.3 Statistical analysis 
The statistical analysis of the MaxQuant results was done in Perseus 
(Version1.5.0.31). At first, proteins only identified by one peptide were 
removed. Relative protein quantification was done based on LFQ intensities 
of at least two unique and razor peptides per protein. Significant protein 
expression differences between the two groups were identified using a T-test 
analysis with a P value < 0.05. 
6.18.4 GO analysis 
The two lists of the differentially expressed proteins were subjected to 
PANTHER classification system, version 9.0 (http://www.pantherdb.org/), for 
molecular function-based gene ontology analysis. Genes were categorized 
into multiple different functional groups, including binding, catalytic activity, 
enzyme regulator, nucleic acid binding transcription factor activity, protein 
binding transcription factor activity, receptor activity, structure molecule 
activity, transporter activity, and others. 
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6.19 Orthotopic pancreatic cancer xenografts in immunodeficient mice 
The orthotopic implantation was performed as reported in [382]. 
Briefly, female, 5 weeks old Severe Combined Immunodeficiency (SCID) mice 
were anesthetized by inhalation of isoflurane (4% for the induction and “% for 
the maintenance). The abdomens were shaved and prepped with a betadine 
solution. The entire operation was done in a sterile hood, with sterile 
technique maintained throughout. A 1-cm incision was made in the left upper 
quadrant of the abdomen, and the pancreas was exposed by retraction of the 
spleen. 1 x 106 MIA PaCa-2 wild type, MIA PaCa-2 PGS and MIA PaCa-2 
ANXA1 KO were resuspended in a mixture of 20 μl of sterile PBS and 20 μl of 
matrigel (BD Transduction Laboratories) (1:1) and injected directly into the 
pancreas of, using a 29 gauge needle of a Hamilton syringe. The peritoneum 
was then closed with 5.0 dissolvable suture (AgnTho´s AB) and the skin 
incision closed with wound clips (Azlet). After 5 weeks from the implantation, 
mice were sacrificed and organs like pancreas with tumor mass and liver 
were collected and analyzed.  
6.20 H&E tissue staining 
The livers were harvested, whashed in PBS 1x and fixed in a solution 
of p-formaldehyde and TritonX-100 (0.5% and 0.1% v/v in PBS, respectively) 
O/N at 4°C. Then they were incubated in a sucrose solution (15% p/v in 
deionized water) O/N at 4°C to guarantee the cryoprotection. The organs 
were cut into two parts, mounted in OCT and immediately frozen in isobutyl 
alcohol mixed with dry ice. The obtained blocks were stored at -80°C. Frozen 
liver sections were cut on a Leica CM 1950 cryostat at 10–12 μm, mounted 
directly on super frost slides (Thermo Scientific), and air dried for 10–30 min 
before processing for hematoxylin and eosin (H&E) staining. Slides mounted 
cryostat sections were dehydrated for 5 min with acetone previously refreshed 
at -20°C for 15 min and rehydrated to water. Slides were placed in 
hematoxylin stain for 9 min, rinsed in alcoholic acid, differentiated in 80% 
alcohol and stained in 0.01% eosin for 2.5 min, rinsed in 95% ethanol, 
dehydrated with absolute ethanol and cleared in xylenes for 4 min before 
coverslipping with a mix of xylenes:mounting 1:1. The images were taken 
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6.21 Statistical analysis  
All results are the mean ± SEM of at least 3 experiments performed in 
triplicate. The optical density of the protein bands detected by Western 
blotting was normalized against tubulin levels. Statistical comparisons 
between groups were made using two-way ANOVA or unpaired, two-tailed t-
test comparing two variables. Differences were considered significant if 
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7.1 Expression of ANXA1 in PC cell lines  
ANXA1 role in PC progression is poorly described. Therefore, we 
initially focused to define how ANXA1 is expressed and localized in several 
human primary PC cell lines like MIA PaCa-2, PANC-1, BxPC-3 and Capan-2. 
These cells show many differences about their origin, genotype and 
phenotype, as adhesion, migration, invasion and angiogenesis capacities 
[383]. Particularly: 
 BxPC-3 was cultured from a 61-year-old woman’s adenocarcinoma of the 
body of the pancreas [384].  
 Capan-2 originated from a 56-year-old male with pancreatic 
adenocarcinoma. The primary tumor involved the head of the pancreas 
and infiltrated the duodenal wall distal to the ampulla [385]. 
 MIA PaCa-2 was derived from the pancreas adenocarcinoma of a 65-year-
old man, the tumor involved the body and tail of the pancreas and had 
infiltrated the periaortic area [386]. 
 PANC-1 was cultured from a 56-year-old male with an adenocarcinoma in 
the head of the pancreas which invaded the duodenal wall. Metastases in 
one peripancreatic lymph node were discovered during a 
pancreaticoduodenectomy [387]. 




Table 7.1: The four most common mutations in pancreas cancer (WT—wild type, Δ—
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Western blotting analysis in figure 7.1 showed that all cell lines 
expressed ANXA1. Only MIA PaCa-2 cells revealed two bends for ANXA1 (37 
and 33kDa) at variance with the other cell lines (see the paragraph 7.4). 
 
 
Figure 7.1: Total ANXA1 expression in MIA PaCa-2, PANC-1, BxPC-3 and CAPAN-2 
cells was analyzed by Western blot with anti-ANXA1 antibody. Protein normalization 
was performed on tubulin level. 
 
Next, we characterized MIA PaCa-2, PANC-1, BxPC3 and CAPAN-2 
cells on the basis of their phenotype since the more aggressive and invasive 
cancer cells had a higher basal EMT signature [388]. Confocal microscopy 
analyses confirmed more aggressive features for MIA PaCa-2 and PANC-1 
as, differently from BxPC-3 and CAPAN-2, these cancer cells possess a 
marked mesenchymal phenotype characterized by up-regulation of the 
mesenchymal marker vimentin and down-regulation of the epithelial marker 
E-cadherin (Figure 7.2 A, B, C) [168]. 
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Figure 7.2: A, Cultured human MIA PaCa-2, PANC-1, BxPC-3 and CAPAN-2 cells 
fixed and labeled with fluorescent antibody against E-cadherin and Vimentin (green). 
C, Quantitative analysis of E-cadherin expression in MIA PaCa-2, PANC-1, BxPC-3 
and CAPAN-2 cells. D, Quantitative analysis of vimentin expression in MIA PaCa-2, 
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7.2 Localization of ANXA1 in PC cell lines  
Tumor cell invasion and metastasis processes involve many proteins 
that are required for normal cell motility. As it is known that ANXA1 plays a 
role in normal cell migration [345; 346] and in cancer cell invasion and 
metastasis [296; 289], we also analyzed by confocal microscopy ANXA1 
localization in the cellular motility structures identified by using focal adhesion 
kinase (FAK) or F-actin staining. In the figure 7.3 (panels c, f) we show that 
ANXA1 co-localized in both MIA PaCa-2 and PANC-1 cells with FAK, a 
protein commonly expressed in adhesion hot spots of migrating/invasive cells. 
Moreover, we show an actin-like filamentous ANXA1 organization and an 
enrichment of the protein at burble ends and extrusions in MIA PaCa-2 cells 
(Fig. 7.3, panel i). Also in PANC-1 cells ANXA1 co-localized with F-actin 
protein although this cell line is characterized by a less mesenchymal-like 




Figure 7.3: Immunofluorescence analysis to detect FAK (panels a, d), ANXA1 
(panels b, e, h, m), and F-actin (panels g, l) in MIA PaCa-2 and PANC-1. Nuclei were 
stained with DAPI. The merged image shows overlapping localization of the proteins 
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(panels c, f, I, n). Magnification 63x.The data are representative of 5 experiments with 
similar results. Bar=10µm. 
7.3 Effects of ANXA1 knockdown on MIA PaCa-2 and PANC-1 cell 
migration and invasiveness 
As it is known from previous reports and confirmed by our data using 
confocal microscopy, PANC-1 and MIA PaCa-2, at variance with CAPAN-2 
and BxPC-3, show a more aggressive phenotype, particularly MIA PaCa-2 
that have an higher tumorigenic potential [383; 389].  
We observed that in MIA PaCa-2 and PANC-1 cell lines, ANXA1 
localized in the regions that are involved in the cell movement. As the 
migration and invasion processes start once cells form actin- and FAK-rich 
protrusions that adhere to the matrix and create the tension forces necessary 
for cell motility [390], we hypothesised a role for the protein in these 
processes. The expression of ANXA1 was greatly reduced in MIA PaCa-2 
(Fig. 7.4A) and PANC-1 (Fig. 7.4D) cells by specific siRNA transfection. Thus 
a Wound healing migration assay was performed on cellular monolayer of 
ANXA1 knockdown cells. The confluent cultures were scraped at the middle 
of well to create a wound and cell migration was monitored by time-lapse 
video-microscopy at the site of the described wound. We measured the 
migration distances of selected cells at different time points as described in 
Material and methods section. In ANXA1 knockdown MIA PaCa-2 (Fig. 7.4B) 
and PANC-1 (Fig. 7.4E) cells the rate of migration decreased in a significant 
manner, if compared with the wild type control and with scrambled RNA 
transfected cells.  
The matrigel invasion assay was also performed in ANXA1 knockdown 
MIA PaCa-2 and PANC-1 cells to investigate the role of ANXA1 on their 
invasion ability. As shown in figure 7.4C and 7.4F, siRNAs against ANXA1 
markedly suppressed the invasiveness of both PC cell lines. To confirm the 
technical efficiency of our experiment, we used a serum free control to 
eliminate any chemoattractant condition: in this way we found significantly 
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Figure 7.4: A, Western blot using an anti-ANXA1 antibody on protein extracts from 
MIA PaCa-2 or PANC-1 cells (D) treated or not with siRNAs direct against ANXA1 
(siANXA1). Protein normalization was performed on tubulin levels. B, Results of 
Wound healing assay on MIA PaCa-2 (B) or PANC-1 cells (E) transfected with 
siANXA1s or scrambled siRNAs; ** p<0.01 vs untreated control. The data are 
representative of 5 independent experiments ± SEM. 
Invasiveness rate of MIA PaCa-2 (C) or PANC-1 cells F, In invasion assays a total of 
90,000 cells were transfected or not with siANXA1s (5nM) or scrambled siRNAs 
(5nM) for 72h and plated as described in Material and methods section. Invasiveness 
rate was founded out by counting stained cells on the lower surface of the filters. Data 
represent mean cell counts of 12 separate fields per well ± SEM of 5 experiments. ** 
p<0.01 vs serum free (SF) control; *** p<0.001 vs SF control; 
###
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7.4 Localization and cleavage of endogenous ANXA1 in MIA PaCa-2 and 
PANC-1 cells 
Cellular migration and invasion events can be triggered by a number 
of molecular signals, such as chemoattractants and mechanical forces, that 
are sensed by receptors on the cell surface or within cells to lead to a 
migratory response [391]. 
The extracellular form of ANXA1 has been described to play a role in 
cancer cell invasion and metastasis. Although the protein does not possess 
classical signal sequences to target the protein for export, both the full-length 
and truncated forms are often observed in extracellular environments. 
Moreover, it appears that proteolytic cleavage of ANXA1 is required for 
protein secretion, because the majority of ANXA1 released from neutrophils is 
N-terminally cleaved [257; 391; 392; 393; 394; 395; 396]. Based on these 
information, our characterization experiments continued with the analysis by 
Western blot of ANXA1 expression in sub-cellular compartments of MIA 
PaCa-2 cells. In particular, we obtained membrane, cytosol and nuclear 
protein extracts as described in Material and methods section. The ANXA1 
membrane expression was detected by both fractioned protein extracts and 
EDTA wash, with which we obtained the proteins that bind plasma membrane 
through calcium. In MIA PaCa-2 extracts, we found both, full length (37kDa) 
and cleaved (33kDa) forms of ANXA1 protein at plasma membrane and in the 
cytosol but not in the nucleus where only the 37kDa ANXA1 form was 
expressed. Conversely, PANC-1 did not show the ANXA1 cleaved form and 
the protein expression in sub-cellular compartments was characterized by a 
small amount onto membrane and in the nucleus, if compared with MIA 
PaCa-2 cells.  
Both full length (37kDa) and cleaved (33kDa) forms of ANXA1 were 
also observed in MIA PaCa-2 supernatants, whereas no protein secretion was 
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Figure 7.5: Cellular compartments were obtained as described in Methods section. 
Total (T), membrane (M), EDTA Wash (EW), cytosolic (C), nuclear (N) and 
supernatants (S) ANXA1 expression in protein extracts from MIA PaCa-2 and PANC-
1 was examined by Western blot with anti-ANXA1 antibody. The protein bands were 
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7.5 Analysis of the secreted forms of ANXA1 
Based on the previous findings, we focused on the appearance of a 
33kDa form only in MIA PaCa-2 cells, both in total (Fig. 7.1) and supernatant 
extracts (Fig. 7.5). Therefore, in order to detect possible ANXA1 fragments 
released from the cells a multi-step fractionation of MIA PaCa-2 supernatants 
was performed. Obtained samples were analyzed by LC-HRMS/MS as 
described in Material and methods section. A peptide showing a molecular 
weight of 2744.324 was detected; on the basis of its molecular weight and of 
the CID induced fragmentation spectrum (Fig. 7.6), this peptide was identified 





Figure 7.6: LC-HRMS/MS spectrum, peaks refer to all the discovered peptide 
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7.6 Expression of FPRs in MIA PaCa-2 and PANC-1 cells 
Cancerous cell capability to migrate and invade tissues is a decisive 
aspect of cancer development and metastasis and entails the coordination of 
several cellular events, such as cytoskeletal reorganization, dynamic cell-
matrix adhesion and remodeling [390].  
Regulatory action on cell surface by extracellular ANXA1 is reported to 
be mediated by signaling through FPRs [345; 346; 397; 283] that are reported 
to regulate cell migration by actin polymerization.  
In order to verify the role of ANXA1-FPR interaction in MIA PaCa-2 
and PANC-1 cell migration and invasiveness, we first assessed FPR 
expression in these cell lines by cytofluorimetric analysis (Fig. 7.7A): we found 
that FPR-1 and FPR-2 were expressed in both cell lines. These findings were 
confirmed by qualitative PCR (Fig. 7.7B).  
 
 
Figure 7.7: A, Cell surface expression of FPR-1 and FPR-2 in MIA PaCa-2 and 
PANC-1 cells was analyzed by flow cytometry. The violet areas in the plots are 
relative to secondary antibody alone. FPR-1 and FPR-2 signals are showed with 
green bends. B, Expression of FPR-1 and FPR-2 in MIA PaCa-2 and PANC-1 cells 
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7.7 Activation of FPRs in MIA PaCa-2 and PANC-1 cells 
 
It is known that the interaction between ANXA1 and FPRs causes a 
series of cellular responses, such as the ERK phosphorylation and the 
increase of intracellular [Ca2+] concentration. The N-terminal mimetic peptide 
of ANXA1, Ac2-26, can activate all three human FPRs, promoting calcium 
fluxes and cell locomotion. To determine whether ligand binding to FPRs 
induces similar signal transduction in MIA PaCa-2 and PANC-1, we examined 
the stimulated release of calcium from intracellular stores. Cells were 
incubated in Ca2+ free medium and loaded with the fluorescent calcium 
indicator Fluo-2AM before stimulation with Ac2-26 (1 µM) or the natural FPR 
agonist fMLP (50 nM) together or not with the FPR pharmacological 
antagonist Boc-1 (10 µM) that is able to antagonize, at this concentration, all 
three human FPR isoforms. The spectrofluorimetric assay (Fig. 7.8) shows 
that fMLP and peptide Ac2-26 were able to increase the mobilization of 
intracellular Ca2+ in both MIA PaCa-2  and PANC-1 cells. In fact, no significant 
differences between ionomycin (used as reference compound) and fMLP or 
Ac2-26 were observed. The effects of fMLP and Ac2-26 peptides were 
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Figure 7.8: Effects of fMLP (50 nM), Ac-2-26 (1 µM) and FPR pan-antagonist Boc-1 
(10 µM) on the FPR-induced rise in intracellular Ca
2+
 in MIA PaCa-2 or PANC-1 cells. 
The histograms show the fluorescence ratio calculated as F340/F380 nm in absence 
of extracellular Ca
2+
. Control represents ionomycin-stimulated cells. Data are means 
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7.8 Effects of activation of FPRs on MIA PaCa-2 and PANC-1 cells in 
migration and invasion assays 
The role of ANXA1 in cancer progression is still discussed; this protein 
may have specific functions in different tumoral models. For example, in 
gastric and colon carcinomas ANXA1 has a pro-invasive role through its 
interaction with FPRs [347; 283].To determine if ANXA1 influences cell 
migration acting through FPRs, we performed a Wound healing migration 
assay on cellular monolayer in both the analyzed cell lines. 
For MIA PaCa-2, results in figure 7.9A show an increase in migration 
speed of cells treated with Ac2-26 (1 µM) or fMLP (50 nM) compared to 
control cells. The FPR pan-antagonist Boc-1 (10 µM) significantly inhibited 
basal and stimulated migration. When treated with Ac2-26 and fMLP, MIA 
PaCa-2 cells showed an increased invasion speed through coating of 
matrigel. Again, Boc-1 antagonist (10 µM, Fig. 7.9C) reduced in a significant 
manner MIA PaCa-2 stimulated cell invasion.  
At the same time, we used PANC-1 cell line as basis for comparison, 
as these cells did not show either the ANXA1 cleaved form or the externalized 
one. Similarly for MIA PaCa-2, results of the Wound healing migration assay 
on cellular monolayer showed an increase in migration speed of the cells 
treated with Ac2-26 or fMLP when compared to control cells and a reverted 
effect in cells treated with the pan-antagonist Boc-1 (Fig. 7.9B and D). 
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Figure 7.9: Wound healing assay on MIA PaCa-2 (A) or PANC-1 cells (B) treated or 
not with fMLP (50nM), Ac2-26 (1µM), Boc-1 (10 µM), fMLP + Boc-1 or Ac2-26 + Boc-
1; * p<0.05, ** p<0.01, *** p<0.001 vs untreated control; 
##
 p<0.01 and 
§§
 p<0.01 vs 
respective controls. Invasiveness rates were measured as described in Material and 
methods section and are represented in C for MIA PaCa-2 and D for PANC.1. Data 
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7.9 Effects of extracellular ANXA1 on MIA PaCa-2 and PANC-1 cells in 
migration and invasion assays 
To confirm the direct effect of extracellular ANXA1 on MIA PaCa-2 and 
PANC-1 cells, we used an ANXA1 blocking antibody showing its ability to 
reduce in a significant manner MIA PaCa-2 basal cell migration (Fig. 7.10A) 
and invasion (Fig. 7.10C). Interestingly, ANXA1 blocking antibody had no 
effects on PANC-1 cell motility, both about migration ability (Fig. 7.10B) and 
invasiveness (Fig. 7.10D), confirming the absence of its targeted protein in 
the extracellular environment for this cell line.  
 
 
Figure 7.10: Wound-healing assay on MIA PaCa-2 (A) or PANC-1 cells (B) treated or 
not with ANXA1 blocking antibody (AbANXA1) or scrambled rabbit IgG (IgG R); *** 
p<0.001 vs untreated control. All wound-healing data are representative of 5 
experiments ± SEM. Invasiveness rate of MIA PaCa-2 (C) or PANC-1 cells (D) 
treated or not with AbANXA1 or IgG R; *** p<0.001 vs untreated control. Invasiveness 
rates were measured as described in Methods section. Data represent mean cell 
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7.10 Effects of MIA PaCa-2 supernatants on PANC-1 cell migration 
Our data suggest a double role of ANXA1 in PC cell motility. In one 
way the protein acts in the intracellular environment thanks to its involvement 
in cytoskeleton reorganization, as confirmed by immunofluorescence assay 
showed in figure 7.3. In another one, ANXA1 externalized form appears to 
bind FPRs and trigger some molecular pathways that lead to cell migration 
and invasion. Substantial evidences support that ANXA1 membrane 
translocation and its consequent externalization are modulated by some post-
transductional modifications. In particular, Ser27 phosphorylation triggers a 
proteolytic cleavage by which protein loses its N-terminal fragment [257]. As 
previously described, the greater part of biological ANXA1 activity is due to 
this peptide which is especially important in several extracellular functions of 
the protein [398].  
Furthermore, we considered the higher migratory and invasive rate of 
MIA PaCa-2 compared with PANC-1 cells [383]. In order to confirm that the 
secreted forms of ANXA1 protein were able to induce PC cell migration and 
invasion in autocrine and paracrine manner, we performed further 
experiments adding MIA PaCa-2 supernatants to PANC-1 cells and 
viceversa. As shown in figures 7.5 and 7.6, MIA PaCa-2 supernatants 
containing all the secreted forms of ANXA1 protein (37kDa, 33kDa and 3kDa) 
significantly increased PANC-1 cell migration rate. Conversely, the 
administration of PANC-1 supernatants on MIA PaCa-2 cells had no effects 
on migration speed of the latter ones. Moreover, the administration of MIA 
PaCa-2 conditioned supernatant containing ANXA1 blocking antibody on 




Figure 7.11: Effects of MIA PaCa-2 supernatants on PANC-1 cells and viceversa in a 
Wound healing assay. *** p<0.001. Data are means ± SEM (n=5). 
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7.11 Creation of genomic ANXA1 deletion in MIA PaCa-2 cell line using 
CRISPR/Cas9 technique 
Working with cellular model systems, RNAi (as in case of siRNA) has 
represented a powerful tool for functional genomics. However, limitations of 
this approach have included incomplete reduction in target mRNA transcript 
levels, heterogeneity of effect of independent reagents targeting the same 
gene and known off-target effects including seed-based and non-seed effects. 
Genome editing strategies promise to address many of these concerns and 
represent an exciting, complementary approach for prospective genetic 
perturbation [399]. Therefore, we opted for the use of CRISPR/Cas9 
technique, as reported in Material and Methods section, to obtain the genomic 
deletion of ANXA1 gene. 
Plasmid map and specific sequence targeting a small portion (from 
nucleotide 274 to 292) of ANXA1 coding sequence are represented in figure 
7.12A and B, respectively. We obtained 12 ANXA1 knockout (KO) clones of 
MIA PaCa-2 cell line which has been chosen because of its aggressive 
phenotype and the marked in vivo tumorigenity. ANXA1-KO clones were all 
analyzed by Western blotting. In figure 7.12C only 3 of them are reported and 
compared with MIA PaCa-2 wild type (WT) and the scrambled vector (PGS), 
used as technical and biological controls. The expression of ANXA1 has been 
normalized considering tubulin levels.  
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Figure 7.12: A, Commercial plasmid map; B, Targeting sequence of plasmid, the 
sequence of alignment are signed by green arrows; C, B11, D6, G2 and G5 are 4 of 
12 clones KO for ANXA1, the absence of ANXA1 has been compared with MIA 
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7.12 Comparative proteomic analysis of MIA PaCa-2 PGS and ANXA1 KO 
derived sub-line MIA PaCa-2 
Once we obtained ANXA1 KO-MIA PaCa-2 from MIA PaCa-2 WT cells 
as previously described, we examined the total protein extract by LC-MS/MS 
together with MIA PaCa-2 PGS to characterize proteins putatively affected by 
the absence of ANXA1. Also MIA PaCa-2 WT cells were analyzed but no 
significant differences were found when compared to PGS protein extract The 
adopted procedure has been described in detail in Material and Methods 
section. The total protein extract was performed in biological triplicate and 
three ANXA1-KO clones have been taken. According to the statistic tests, in 
ANXA1 KO MIA PaCa-2 26 proteins appear down-modulated, on the other 
hand, 36 were over-expressed. These proteins belong to pathways involving 
several processes which are represented in the pie chart in figure 7.13A. 
They are metabolism, cell proliferation, cell trafficking, cytoskeleton 
organization and other processes. We paid particular attention about this 
cytoskeleton organization signaling because the importance that ANXA1 has 
in remodeling of F-actin and other correlated proteins. The proteins are 
reported in table 7.13B and they are specified by fold change, relative p value 
(for all < 0,05) and the gene name.  
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Figure 7.13:A, Pie chart of the different cell pathways affected by the absence of 
ANXA1; B, Differentially expressed proteins identified by mass spectrometry involved 
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7.13 Validation of protein identified as differentially expressed in the LC-
MS/MS analysis 
To validate the LC-MS/MS-obtained results, as well as to further 
evaluate the nature and importance of some of the identified proteins that 
changed expression between ANXA1 KO MIA PaCa-2 and MIA PaCa-2 PGS 
cells lines, other kinds of experiments have been performed.  
Of particular note, ANXA1 KO MIA PaCa-2 showed reduced 
expression of of vimentin, a protein of the intermediate cytoskeletal filaments 
and a known EMT marker. We confirmed the down-modulation of this protein 
by Western blot analysis, as shown in figure 7.14A, and by 
immunofluorescence assay (Fig.7.14D, panel g, h, i). Moreover we 
established also the down-modulation of Lamin A/C (Fig. 7.14D, panel l, m, 
n), another protein belonging to the cytoskeletal intermediate filaments, which 
apperas misregulated in some cancers. The lamins are components of the 
nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear 
membrane which is suggested to provide a framework for the nuclear 
envelope and may interact with chromatin. Nuclei are mechanically linked to 
the cytoskeleton through lamin-interacting proteins that span the nuclear 
envelope. Nuclear lamina also mediates structural linkages between the 
nucleus and cytoskeleton, through the linker of nucleoskeleton and 
cytoskeleton (LINC) complex just consisting of lamins and an interacting outer 
nuclear membrane protein, which in turn binds cytoskeletal elements [400]. 
Furthermore, we demonstrated the increase of CD44 level by FACS 
technique, using APC-conjugated antibody. CD44 has a particular importance 
in cell adhesion on hyaluronic acid of ECM, in fact only when it undergoes a 
proteolytic cleavage, it becomes not more capable to guarantee the adhesion 
and cell begin to migrate [401; 402; 403]. In figure 7.14B, the purple line is 
overlapped on the green one and they respectively refer to the CD44 
expression in MIA PaCa-2 PGS and in MIA PaCa-2 WT; the black line is 
relative to the protein expression in ANXA1 KO MIA PaCa-2 and, finally, the 
blue line refers to the APC-conjugated human IgG1 using as technical control.  
Cytokeratin 8 (CK8) and 18 (CK18) have a structural role in simple 
epithelia. Additionally, they play a role in a signaling that modulates cell 
attachment, protein synthesis, G1/S phase transition, and in stress 
adaptation. Furthermore, CK18 can be applied to detect therapy-induced 
tumor apoptosis and necrosis [404; 405; 406]. Several reports showed that 
there is an inversely correlation between CK18 and ANXA1 expression, such 
as in our case [298]. By RT-PCR in figure 7.14C, executed as reported in 
Material and method section, we showed the increase of cytokeratin (CK) 18, 
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using the levels of the protein hypoxanthine phosphoribosyltransferase 1 
(HPRT) as house-keeping gene. Additionally, the Western blot in figure 7.14A 
proved the increase of CK8.  
Cell migration requires precise control, which is altered or lost when 
tumor cells become invasive and metastatic. The first protein we analyzed 
was F-actin because of its important role in cell migration. In fact, its 
polymerization mediates the mechanical energy to induce the formation of 
lamellopodia. These ones are characterized by a network of actin and myosin; 
particularly actin spreads out in parallel bundles to mediate the interaction 
with integrins and other focal adhesion molecules. In this way the cell 
directional advancing is guaranteed [407]. ANXA1 co-localizes with F-actin in 
the basal conditions, that is in cells in which the cytoskeleton protein is well 
spread in filamentous and organized in bundles protruding towards the 
plasma membrane. On the contrary, in ANXA1 KO MIA PaCa-2 cells we 
found a disorganized cytoskeleton and F-actin appeared concentrated all 
around plasma membrane and depolymerized in the cytosol. This is known as 
cortical F-actin and is not capable to induce cell migration as previously 
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Figure 7.14: A, Western blot showing CK8, vimentin, ANXA1 and GAPDH expression 
on MIA PaCa-2 WT, PGS and ANXA1 KO. B, Cell surface expression of CD44 was 
analyzed by flow cytometry. The violet areas in the plots are relative to human IgG1; 
CD44 signals are showed with green bends for MIA PaCa-2 WT, in pink bends for 
MIA PaCa-2 PGS and in black ones for MIA PaCa-2 ANXA1 KO. C, RT-PCR for 
CK18 mRNA expression measured on levels of HPRT in the same experimental 
models. D, Immunofluorescence analysis to detect ANXA1 (panels a, b, c), F-actin 
(panels d, e, f) vimentin (panels g, h, i) and Lamin A/C (panel l, m, n) in MIA PaCa-2 
WT, PGS and ANXA1 KO. Nuclei were stained with DAPI. The merged image shows 
overlapping localization of the proteins (panels c, f, I, n). Magnification 63x. 
Bar=10µm.  
The results relative to ANXA1 KO MIA PaCa-2 are representative to almost three 












CHAPTER 7                                                                                                       Results 
 
- 107 - 
 
7.14 Effects of ANXA1 knockout on MIA PaCa-2 migration and invasion 
Based on the information by immunoflurescence assay particularly 
about the F-actin distribution and in order to confirm the previous data with 
ANXA1 siRNA, we performed the same functional assays to analyze the 
migration and invasion ability of ANXA1 KO MIA PaCa-2 cells. Both Wound 
healing assay and invasion through coating of matrigel were executed on 
three KO clones compared with WT and PGS cells. In figure 7.15 it is possible 
to observe a significant reduction of migration rate (about the 40%) (Fig. 
7.15A and B) and a stronger loss of invasion capability (about the 80%) 
(Fig.7.15C and D). Also in this case, the invasion experiment was performed 




Figure 7.15: A, Results of Wound healing assay on ANXA1 KO MIA PaCa-2; ** 
p<0.01 vs untreated control. The data are representative of 5 independent 
experiments ± SEM. B, Representative images captured by TIME LAPSE microscope 
of the migration process of MIA PaCa-2 WT, PGS and ANXA1 KO. 
C, Invasiveness rate of ANXA1 KO MIA PaCa-2. Data represent mean cell counts of 
12 separate fields per well ± SEM of 5 experiments. D, Representative imagines of 
analyzed fields of invasion assay. 
 ** p<0.01 vs serum free (SF) control; *** p<0.001 vs SF control; 
###
 p<0.001 vs 
control. 
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7.15 ANXA1 KO MIA PaCa-2 cells respond to the pro-migratory and pro-
invasive effects of Ac2-26 
The proteomic study has not identified any modification in the 
expression of the main proteins which are involved in the intracellular 
signaling triggered by FPRs. Furthermore, both FPR-1 and FPR-2 
expressions are retained in MIA PaCa-2 ANXA1 KO compared with MIA 
PaCa-2 WT and PGS, as shown by cytofluorimetric assay in figure 7.16A. In 
order to confirm the activation of FPRs pathways in MIA PaCa-2 ANXA1 KO 
clones, receptor agonist (Ac2-26) and antagonist (Boc-1) have been used in 
migration and invasion assays. Both Wound healing assay and cell invasion 
through the coating of matrigel confirmed that Ac-2-26, the ANXA1 mimetic 
peptide, induced a significant increase of migration and invasion rate if 
compared with the controls. Interestingly, when treated with Ac2-26, MIA 
PaCa-2 KO clones migrate and invade in a very similar way of control MIA 
PaCa-2 WT and PGS, as evident in figure 7.16B and 7.16C, reporting the 
invasion assay. In the same manner of MIA PaCa-2 WT and PGS, Boc-1 







CHAPTER 7                                                                                                       Results 
 




Figure 7.16: A, Cell surface expression of FPR-1 and FPR-2 in MIA PaCa-2 WT, 
PGS and ANXA1 KO cells was analyzed by flow cytometry. The violet areas in the 
plots are relative to secondary antibody alone. FPR-1 and FPR-2 signals are showed 
with green bends. B, Wound Healing assay on MIA PaCa-2 ANXA1 KO treated or not 
with Ac2-26 (1µM), Boc-1 (10 µM) and Ac2-26 + Boc-1. The migration rate has been 
calculated as reported in Material and methods section, ** p<0.01 vs all the other 
experimental points. Invasiveness rates were measured in C** p<0.01 and *** 
p<0.001 vs untreated control and 
◘◘◘
 p<0.001 vs MIA PaCa-2 WT and PGS not 
treated controls. Data represent mean cell counts of 12 separate fields per well ± 
SEM of 5 independent experiments. The data relative to clone ANXA1 KO are 
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7.16 Effects of ANXA1 knockout on MIA PaCa-2 proliferation 
Based on the information obtained thanks to proteomic analysis, to 
complete the investigation of the functional role of ANXA1 in our experimental 
models, we analyzed also cell growth and proliferation rate. Therefore, 
ANXA1 KO MIA PaCa-2 show a faster propagation rate with respect to MIA 
PaCa-2 WT and PGS technical control. So, through an MTT assay, the result 
was confirmed as shown in the graph in figure 7.17A. The major proliferative 
capacity of these cells is represented also by a more prompted cell cycle in 
the direction of S/G2 phases (Fig. 7.17B). For this reason we analyzed by 
Western blot the expression of other proteins that could play a critical role, 
using antibody against the Cyclin A (Fig. 7.17C). Cyclin A is particularly 
interesting among the cyclin family because it can activate two different 
cyclin-dependent kinases (CDKs), CDC2 and CDK2, and functions in both S 
phase and mitosis, it starts to accumulate during S phase and is abruptly 
destroyed before metaphase implicating the control of DNA replication; 
ectopic expression of cyclin A in mammalian cells accelerates the entry of G1 
cells into S phase [408]. Furthermore, confirming the data obtained by the 
proteomic analysis, we showed also the increase of Aldehyde 
dehydrogenase7A1 (ALDH7A1), by Western blot shown in figure 7.17D. This 
is a protein mainly involved in the process of cell detoxification, as it is a 
member of the alcohol metabolism, but there are several experimental data 
which correlated ALDH7A1 cytosol localization with the regulation of cell 
cycle. Particularly, in some tumor models, the effects of tumorigenic signals 
induce the increase of protein expression. In addition, it has been reported 
that using shALDH7A1, the levels of cyclin A significantly decrease [409; 410] 
On the other hand, the classical ERK family (p42/44 MAPK) is known 
to be an intracellular checkpoint for cellular mitogenesis: in cultured cell lines, 
mitogenic stimulation by growth factors correlated with stimulation of p42/44 
MAP kinase [411]. After the activation of receptor tyrosine kinases (RTKs) or 
GPCRs by growth factors or mitogens several signals are triggered until the 
phosphorylation of ERK1/2 by MEK1/2, on both threonine and tyrosine. The 
phosphorylated ERK1/2 translocate to the nucleus where they activates 
multiple transcription factors ultimately resulting in effector protein synthesis 
and causing changes in cell proliferation and survival [412]. The increase of 
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Figure 7.17: A, MTT assay at 24, 28 and 72h on MIA PaCa-2 WT, PGS and ANXA1 
KO (clones B11, D6, G2, G4 and G5). B, Cell cycle analysis thorough PI staining, the 
graph is representative of 72h of culture, after 24h of serum starvation. 
C, Western blot of Cyclin A expression on the same experimental points. D, Western 
blot showing ALDH7A1 expression. E, ERK and phospho-ERK on MIA PaCa-2 WT, 
PGS and ANXA1 KO clones as B11, D6 and G5. All protein levels are normalized on 
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7.17 ANXA1 is not involved in apoptosis induced by gemcitabine 
In several system, such as tumoral or inflammatory ones, ANXA1 has 
been described as a protein involved in apoptosis mechanisms. In PC system 
there is no evidences about this aspect. However we investigated the 
apoptosis induced by gemcitabine, the false nucleotide still used in PC 
chemotherapy, to test the sensitivity of MIA PaCa-2 ANXA1 KO compared to 
MIA PaCa-2 WT and PGS. Generally, MIA PaCa-2 cell line does not answer 
significantly to gemcitabine and cells appear quite resistant to lots of 
chemotherapic molecules, probably due to the membrane expression of high 
levels of MUC1 and MUC4 that increase the phosphorylation of pro-apoptotic 
protein Bad in association with the increased phosphorylation of HER2 and 
ERK [131; 134]. As reported in figure 7.18, MIA PaCa-2 cells show a worthy 
sensitivity to gemcitabine 10 µM only at 72h and there are no significant 
changes in response to the molecule among WT, PGS and ANXA1 KO cells. 




Figure 7.18: Analysis of hypodiploid (apoptotic) nuclei by cytofluorimetric assay of the 
effect of gemcitabine 10 µM at 24, 4 and 72h on MIA PaCa-2 WT, PGS and three 
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7.18 KO of ANXA1 decreases the metastatic potential of highly 
aggressive MIA PaCa-2 cells in vivo 
 
Since the initial phases of the study about cancer of the digestive 
apparatus, MIA PaCa-2 cells were chosen to establish human pancreatic 
tumor xenografts both for subcutaneous and orthotopic models [413]. In order 
to validate in vivo the data collected in vitro about the effect of ANXA1 in PC 
progression, the generated cell lines were implanted directly into the pancreas 
of SCID female mice as reported in Material and methods section. The animal 
wellness has been checked during all the experimental period evaluating their 
motility and measuring once a week the weight: no significant weight loss has 
been found, (Fig.7.19A). After 5 weeks from the implantation, mice were 
sacrificed and the tumors generated in the pancreas were evaluated. KO of 
ANXA1 had no effect on primary cancer growth. As shown in figure 7.19B, the 
tumor mass in mice implanted with MIA PaCa-2 ANXA1 KO did not appear 
smaller in a significant manner if compared with those extracted from mice 
implanted with MIA PaCa-2 WT and PGS. This aspect is confirmed also 
through the evaluation of tumor weight displayed in the graph in figure 7.19C. 
But we also determined whether ANXA1 depletion from highly invasive MIA 
PaCa-2 cells can reduce metastasis formation. For this purpose, we analyzed 
the livers of the animals since they represent the first affected organ form PC 
metastatic process. The livers harvested from mice injected with MIA PaCa-2 
WT and PGS presented numerous metastasis which were particularly notable 
since they emerged as white spots on the surface of a brick-red organ. 
Additionally, the interested livers lost their own physiological integrity with 
indented profiles and reduced compactness. On the other hand, the livers 
extracted from the animals implanted with MIA PaCa-2 ANXA1 KO retained 
their characteristic colour and tissue density and showed reduced metastatic 
lesions (Fig. 17.9D). Furthermore, the tissues processed with H&E (Fig. 
17.9E) revealed distinctly stained areas in a well defined larger zone. It is 
possible to highlight smaller cells with a different morphology and staining in 
the upper areas of the H&E images of the relavite MIA PaCa-2 WT and PGS 
mice livers. The image of the liver of mice implanted with ANXA1 KO MIA 
PaCa-2 cells revealed a more regular tissue. These findings on the liver 
sections confirm the infiltration of tumor metastasis. 
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Figure 7.19: A, Average body weight of mice measured weekly from the implantation 
until the sacrifice. B, An exemplar image, including also the spleens, of the tumor 
volumes generated in pancreas by MIA PaCa-2 WT, PGS and MIA PaCa-2 ANXA1 
KO. C, Histogram of tumor weights. D, Photos of mice livers, the selected areas 
represented the parts affected by metastatic lesions. E, The relative liver sections 
have been stained through H&E. Bar=100µm.  
The results relative to ANXA1 KO MIA PaCa-2 are representative to almost three 
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ANXA1 is the first characterized member of annexin superfamily, it 
was discovered as an antinflammatory protein but, in the last 20 years, 
ANXA1 has been involved in a broad range of molecular and cellular 
processes, including inhibition of cell proliferation, the regulation of cell 
migration, differentiation and death both in physiological and pathological 
models [414]. In tumors ANXA1 performs multiple functions and it appears to 
behave either as a tumour suppressor or an oncogenic gene. More studies 
are required to investigate in detail the role of ANXA1 in cancer progression 
since its mechanism of action has not been yet completely clarified. 
About its involvement as oncogenic factor, ANXA1 participates in the 
maintenance of a stem-like/aggressive phenotype in prostatic carcinoma, 
where the protein seems overall down-modulated [287]. On the other hand 
ANXA1 contributes to tumor progression inducing cell migration and invasion, 
leading to metastatization, drug-resistance and poor prognosis, as shown in 
breast cancer, colon and gastric carcinoma and melanoma, all tumors where 
the protein is up-regulated [287; 289; 290; 282; 283; 296; 299; 415].  
It has been shown that ANXA1 over-expression in the tissues from 
patients with PC is correlated with poor differentiation and prognosis and 
seems to be associated with malignant transformation and cancer 
development [302; 303].  
Furthermore, in PC there is an abnormally high expression of a 
number of important tyrosine kinase growth factors and receptors, like the 
EGF family, which may contribute to the neoplasia growth by autocrine and 
paracrine effects. Immunohistochemistry studies showed that EGFR over-
expression positively correlates with advanced tumor staging and lymph node 
metastasis [303; 416]. For example, activating mutations of the K-ras 
oncogene have also been shown to promote a remarkable array of cellular 
effects such as proliferation, survival and invasion with poor prognosis and 
poor response to many existing therapies [17; 70]. ANXA1 is commonly 
reported as a substrate of EGFR, which is involved in the post-transductional 
modifications (phosphorylations) that the protein undergoes to be, later, 
cleaved and/or translocated to other sub-cellular compartments, above all to 
plasma membrane. In PC the constantly activated EGFR pathway could 
promote ANXA1 up-regulation and modifications which might be associated 
with PC acquired aggressive behavior.  
In this PhD project, we report that ANXA1 might have a role in PC cell 
migration and invasiveness and consequently to be involved in the metastatic 
capability in vivo.  
First of all, we started analyzing ANXA1 expression and localization in 
MIA PaCa-2, PANC-1, BxPC-3 and CAPAN-2 PC cell lines and we found that 
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all of them expressed high and similar levels of ANXA1. Many recent 
experimental evidences report that in vitro tumor models could present at 
least two phenotypes that frequently overlap. The better characterized 
phenotypes can be classified in a less aggressive epithelial-like and a more 
aggressive mesenchymal-like ones [163; 389; 383]. In the latter, ANXA1 is 
mainly localized in the regions involved in cellular motility, suggesting an 
intracellular role for the protein in the processes of cell migration/invasion. 
Since CAPAN-2 and BxPC-3 cells show a less aggressive phenotype, we 
chose to use only MIA PaCa-2 and PANC-1 cells that present more marked 
mesenchymal features.  
In particular, concerning cellular motility, ANXA1 actions are exerted in 
the intracellular environment where it contributes to the dynamic 
reorganization of the actin cytoskeleton, but also extracellularly via FPRs in 
autocrine/paracrine manner [417]. For this reason, we first investigated the 
placement of ANXA1 in the sub-cellular compartments involved in motility, 
where the protein co-localizes with FAK and F-actin, two proteins particularly 
known to mediate the migration process [418]. Then, about the second 
aspect, we investigated the expression and activation of FPRs, as ANXA1 
receptor partners. FPRs are expressed in several cellular populations and 
bind a variety of exogenous and endogenous ligands that elicit differential 
biological responses. ANXA1 and its N-terminal mimetic peptide, Ac2-26, are 
endogenous FPR ligands. Flow cytometry and PCR analyses showed that 
MIA PaCa-2 and PANC-1 cells express FPR-1 and FPR-2. Moreover, 
experiments on the mobilization of intracellular calcium have confirmed the 
activity of the FPRs in these cell lines, following stimulation with the Ac2-26 
peptide. We found no receptor activation in presence of Boc-1, a molecule 
that at a dose of 10 µM can be considered as able to block all the three 
receptor isoforms [313].  
To find a functional role of ANXA1, we used specific siRNAs to down-
regulate its expression in both MIA PaCa-2 and PANC-1 cells and we found a 
significant decrease of the migration rate and a marked suppression of the 
invasiveness of these cells, confirming that intracellular ANXA1 is involved in 
PC cell migration/invasion. Exogenous administration of Ac2-26 was also able 
to increase migration speed and invasiveness of cells through coating of 
matrigel, compared to relative controls. The specificity of Ac2-26-induced 
effects on wound closure and invasiveness through the FPRs was confirmed 
by administration of the FPR pan-antagonist Boc-1. These data confirm the 
involvement of the main pathway which follows the activation of FPRs since 
the triggered Rho GTPases pathway is a key regulator of many functions, 
including cell adhesion, chemotaxis and superoxide generation. Particularly, 
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Rac and Cdc42 are involved in the remodeling of the actin cytoskeleton at the 
leading edge of migrating cells. The activation of Cdc42 is thought to release 
the auto-inhibited conformation of the Wiskott–Aldrich syndrome protein 
(WASP), a multi-domain protein that is an activator of the nucleating Arp2/3 
complex [320].  
ANXA1 has been shown to localize to the cell surface of various cell 
types including leukocytes, endothelial cells, lung epithelial cells and 
synoviocytes where it is thought to be important in biological functions [247; 
419; 258; 420]. As previously reported, the ANXA1 translocation to plasma 
membrane and its secretion, through a not yet known mechanism, are 
outcomes of post-transductional modifications and/or proteolytic cleavages. 
These modifications concern Tyr21 which is the target of EGFR kinase and 
Ser27 phosphorylation by PKC that induces a conformational change, 
including proteolytic cleavages, probably related to the described membrane 
aggregation properties [257; 421]. As shown through compartmentalized 
protein extractions, we also report the presence of the full-length form 
(37kDa) accompanied by the appearance of the 33kDa cleavage product of 
ANXA1 only in MIA PaCa-2 cells. Furthermore, these two forms are secreted 
outside the cells, since they appeared in cellular supernatants. LC-HRMS/MS, 
used to characterize secreted forms of ANXA1, showed a peptide with 
molecular weight of 2744.324 demonstrating, for the first time, the presence 
of the fragment 4-26 of ANXA1 in the extracellular environments. Since we 
found that MIA PaCa-2 cells exhibit a strong level of extracellular ANXA1 in all 
the isoforms (37, 33 and 3kDa), we have hypothesized an important role for 
the secreted protein in regulating PC cell migration/invasion. To demonstrate 
this hypothesis, we tested the effect of a blocking antibody which, binding the 
protein, inhibits its binding to FPRs. The effect is the reduction of motility of 
MIA PaCa-2 cells. Our results are consistent with the observed role of ANXA1 
in head neck squamous cancers where the protein over-expression was 
associated with increased tumour invasiveness and metastasis and in SK-
CO15 intestinal epithelial cells where ANXA1 regulated cellular invasive 
behaviour acting through FPRs [422; 283]. Moreover, we showed that ANXA1 
blocking antibody had no effects on PANC-1 cell motility, confirming that, 
differently from MIA PaCa-2, no secreted forms of ANXA1 protein were 
observed in protein supernatant extracts from PANC-1 cells. However, it is 
evident an increase in migration and invasiveness rate of cells treated with 
Ac2-26: these findings are consistent with the expression of FPR-1 and FPR-
2 that we found on the surface of these cells. Consequently, we reasoned on 
the role of the extracellular protein in PC cell line migration and invasiveness 
and we supposed that the more invasive behavior of MIA PaCa-2 than PANC-
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1 cells could be due to the presence of secreted forms of ANXA1 [423; 424]. 
To further confirm this aspect, we found that the addition of MIA PaCa-2 
supernatant to PANC-1 cells significantly stimulated PANC-1 migration rate. 
Conversely, PANC-1 supernatant administration on MIA PaCa-2 cells had no 
effects on cell motility, confirming that the secreted forms of ANXA1 protein 
may be able to induce PC cell migration and invasion [425]. 
Among the other PC cell lines, MIA PaCa-2 cells are commonly used 
to induce tumor xenografts in nude mice because of their strong capability to 
develop not only the largest tumoral mass but also metastasis [383]. So we 
chose this cell line to create KO ANXA1 clone in order to further investigate 
the role of this protein in vitro but above all in vivo. The technology used to 
induce the KO has been the Gene CRISPR/Cas9; this latter makes use of the 
endonuclease activity of the enzyme Cas9, directed to the gene target by a 
gRNA transcripted just by the plasmid. The generated effect consists of a 
DSB on a portion of the targeted coding sequence which will be repaired by 
the NHEJ pathway [365; 366]. Finally we obtained, through the limit dilutions 
approach, the ANXA1 KO clones together with the MIA PaCa-2- PGS, a 
scrambled DNA plasmid we have used as technical control, and the MIA 
PaCa-2 WT. This technology has been devised to prevent off target effects 
that are very common in these experimental setups [370]. To characterize in 
detail the MIA PaCa-2 ANXA1 KO with respect to MIA PaCa-2 PGS and WT, 
a proteomic analysis was performed to evaluate the expression of which 
proteins could be directly or not affected by the absence of ANXA1. Among 
the detected proteins, of particular interest were the proteins of the 
cytoskeleton that are involved in the maintenance of its stability and plasticity. 
In addition, changes in expression of other components of the ANXA family 
were not observed confirming the absence of important off target effects. 
Among the cytoskeleton proteins, the expression of F-actin was not modified 
whilst the phalloidin staining proved a confused distribution in the cytosol and 
the lack of lamellopodia and stress fibers, the well documented sub-cellular 
structures which are known to be assigned to cell motility. It is widely 
accepted that actin stress fibers promote cell migration, forming an assembly 
mechanism which exhibited an uniform polarity, that is pointing towards the 
leading edge, with their constituent filament barbed ends [426]. Since cell 
motility is driven by the assembly of both protrusive and contractile actin 
filaments, the disruption of this organization led us to investigate again the 
migration and invasion processes, confirming their strong reduction in MIA 
PaCa-2 ANXA1 KO. These results, taken together, show that ANXA1, in the 
intracellular environment, directly mediates the cytoskeleton integrity and 
distribution, controlling the rate of the actin filament assembly and 
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disassembly. However, the potential role of extracellular ANXA1 is likely 
retained because the expression and activation of FPRs is not affected by the 
absence of the protein. In fact, in presence of agonist, the Ac2-26 peptide, 
and antagonist, Boc-1, the MIA PaCa-2 ANXA1 KO cells migrate and invade 
following the same trend of the parental control MIA PaCa-2 WT and MIA 
PaCa-2 PGS. Thus, the capability of ANXA1 to act in the extracellular 
environment, binding FPRs and triggering the increase of migration and 
invasion rate, has been further confirmed. 
Based on our findings, it is possible to assert that ANXA1 overall 
contributes to the maintenance of a more aggressive phenotype of PC cells. 
Its KO induces not only a strong decrease of migration and invasion speed, 
but also a greater proliferation rate, a typical aspect of more differentiated 
tumors, which could be, in this way, more easily attacked by the 
chemotherapic agents. Nevertheless, ANXA1 is not involved in the apoptosis 
process mediated by gemcitabine, the main anti-tumoral agent still used in the 
clinical practice.  
With the purpose to investigate the role of ANXA1 in vivo, orthotopic 
xenotrapiants with MIA PaCa-2 WT, PGS and ANXA1 KO have been created 
in SCID mice. ANXA1 KO did not affect primary tumor growth, but significantly 
reduced the number of metastases, above all the liver ones.  
Taken together these results indicate that ANXA1 is important in 
migration and invasiveness of PC cells. Furthermore, it has been shown that 
the EMT process may not be necessary to metastatization: two studies in 
Nature report that EMT is not required for metastasis in mouse tumor models. 
Both in a lung and pancreatic carcinoma models, the EMT suppression did 
not affect the number of circulating tumor cells, the ability of tumor cells to 
form tumor spheres in vitro or the overall frequency of metastasis [427; 428]. 
Moreover, carcinogenesis is a multistep process: to reach the malignant 
phenotype, multiple alterations affecting several levels of growth control are 
required. It is important to consider the origin tissue of tumor; in the case of 
PC, the pancreatic ductal basal cells are an important regulator of the 
differentiation of the pancreatic epithelium. The pancreas is composed of 
simple epithelia with a keratin (CK) profile very similar to liver: the pancreatic 
duct cells exhibit, as the bile duct cells (CKs 7, 19, 20) and the hepatocytes 
have the same CKs as pancreatic acinar cells (CKs 8 and 18), also present in 
the luminal side of ducts (Fig. D.1) [429]. In addition in the pancreas, the 
ductal keratin profile (CKs 7, 19) is associated with poor differentiation and/or 
potential stem cells or progenitors. In epithelia where the location of the 
progenitor cells is known, like for instance the epidermis, this location (basal 
layer) coincides with the distribution of CK 19, whereas the differentiated cells 
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lack CK 19 expression. The CK profile can be actually used to distinguish the 
several phases of physiological morphogenesis, both in the embryonic 
development and in case of damage, and pathological tumor development 
[430]. Particularly, “basalness” has now acquired a dual meaning and could 
be related with an epithelial or progenitor/stem cell origin [431]. The possible 
association between EMT and the existence of a basal-like phenotype has 
been also demonstrated in a study of human breast cancer, suggesting that 
EMT may not be a sign of overall tumor dedifferentiation but, rather, the 
manifestation of a specific phenotype of stem cell origin showing more 
aggressive behavior [180]. In fact, cells with a basal phenotype probably have 
a higher proclivity to develop EMT changes and subsequently undergo 
invasion [432]. Several analysis reported a negative correlation between the 
high expression of the luminal CK 8/18 and the existence of metastasis [296; 
432]. In our ANXA1 KO MIA PaCa-2 cells, we found a significant up 
regulation of the CK couple 8/18, a data that can be considered particularly 
consistent with the acquired ANXA1 KO cells behavior both in vitro and in 
vivo. Our analyses demonstrate an inverse relationship between the presence 
ANXA1 expression and the degree of tumor differentiation, an important 
histopathological criteria in tumor characterization and the definition of 
prognosis for patients.  
 
Figure D.1: the normal pancreatic ducts epithelium is composed of a bilayer 
of basal and luminal cells, these latter are discernible by amylase, among the other 
possible markers, and the CK couple 8/18. It is also synthesized the expansion of 





) in response to oncogenic stimulation. In parallel, the same undifferentiated 
cell has the potentiality to became a luminal one to recover the eventually damaged 
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These findings raise the possibility that ANXA1 could regulate 
metastasis in vivo and may represent a novel approach to cancer treatment. 
However, further studies are needed to address this point. It could be 
interesting to make additional functional studies to determine the role of 
ANXA1 in generating stem-like, so less differentiated, tumor phenotypes and 
to correlate it to PC patients’ prognosis, rate of tumor metastatization, 
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COMPUTATIONAL DESIGN OF PROTEIC INHIBITORS OF ANXA1 
 
A.1 Background 
Annexins participate in membrane-related events such as the 
mediation of membrane-membrane contacts, the regulation of membrane-
cytoskeleton linkages and ion transport across membranes. In this section it is 
described the structural aspect of ANXA1. Generally, it is reported that each 
annexin is composed of two parts, a major C-terminal core domain and a 
minor N-terminal tail domain. The similar properties of all annexins regarding 
Ca2+ and phospholipids seem to be due to the C-terminal core domains that 
show highly conserved sequences and structures. Since the N-terminal tail 
domains of annexins differ widely in length and sequence, it has been 
proposed that these portions can preserve the functional protein specificity. 
Although the 3D structures of more than 10 annexins [433], are presently 
available, the knowledge of the N-terminal domain structure is very scant 
because these domains are either naturally short or truncated [434, 435; 436; 
437]. In this last case, for example, ANXA1 lacks the residues 1-26 since the 
residue Lys-26 is prone to tryptic digestion [437]. 
Annexins are excellent models for studying the folding mechanisms of 
multidomain proteins. All of them have a core domain that contains four (in 
the case of ANXA6 eight) homologous repeats (numbered I to IV) of five α-
helices each. These repeats are arranged into a slightly curved disc with the 
Ca2+-binding sites on the convex side. These N-terminal domains are different 
in sequence and length, varying from a short tail of 11 to 19 residues (ANXA 
3, 4, 5, 6, 10, 12, 13), to 33 to 42 residues (ANXA 2 and 1, respectively), to 
more than 100 residues (ANXA 7 and 11). They harbor binding sites for S100 
proteins (ANXA1: S100A11, ANXA2: S100A10, ANXA11: S100A6) and 
various phosphorylation sites, as in case of ANXA1 and 2, for 
serine/threonine and tyrosine specific kinases.  
Comparative structural analysis suggests that interdomain interactions 
may play critical roles in the folding of ANXA1, it is a symmetric protein and its 
sequences homology is represented in figure A.1. However, the structure of 
ANXA1 can be presented as composed of two modules. One module consists 
of domains I and IV, and the other domains II and III. Each module has a 
hydrophobic interface between its constituents. The two modules are 
assembled with mostly hydrophilic interactions between domains II and IV. It 
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is tempting to speculate that folding of ANXA1 follows a sequential process 
with domain I as an autonomous initial folding unit. The folded structure of 
domain I facilitates the folding of domain IV through the hydrophobic interface. 
Then, the hydrogen bonds and hydrophobic interactions between domains IV 
and II help domain II to get rid of the non-native cap and reach the native 
structure. Domain II, in turn, assists the folding of domain III through many 




Figure 8.1: sequence alignment of the four domains. The hydrophobic core residues 
are shown in yellow and other conserved residues are in blue [439]. 
 
Biochemical studies on the ANXA1-phospholipid interaction have 
shown that the N-terminal domain is important for the aggregation of vesicles 
but not for the binding of ANXA1 to negatively charged phospholipids [440; 
441].  
As reported in figure A.2, the N-terminal ANXA1 peptide contains 41 
residues. The residues 33-41 form an unstructured coil that runs along the 
concave side of the molecule, instead the first 26 amino acid residues of the 
N-terminal domain form two α-helices. The α-helix formed by residues 18-26 
interacts with the surface of repeat IV of the core domain, then, the direction 
of the chain changes at level of the position 17 and the α-helix formed by 
residues 2-16 points turns towards the convex face of the molecule. Finally, 
residues 27-33 can be viewed as an extension of the unstructured strand 
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Figure A.2: overlay of the three-dimensional structures of repeat III (bue) of ANXA1 
plus residues 2-26 to the N-terminal domain (yellow). The yellow arrow indicates the 
direction of the α-helices which are connected to the core domain via an extended 
linker [206] 
 
The structure of an ANXA1 N-terminal peptide comprising residues 2-
12 in complex with the S100A11 protein, in a specific way, was published 
[442]. Furthermore, thermodynamics studies of peptide binding, showed not 
only that this interaction is mediated by calcium ions, but also that it happens 
in a specific way. Particularly, ANXA1 binds S100A11 and, following more 
recent works, also S100A6 even if this interaction is not still characterized 
[443]. Furthermore, the importance of calcium ions was yet described thanks 
to studies based on X-ray-crystallography: in the presence of CaCl2 10 mM 
six calcium ions are found to bind to the truncated ANXAI, two pairs in 
domains I and IV and one pair in domains II and III [439]. 
The N-terminal portion of ANXA1 is also responsible of the interaction 
with another ANXA1 molecule, but, in contrast to the annexin 12 hexamer that 
can also be interpreted as a trimer of dimmers, the ANXA1 dimer does not 
show complete face-to-face orientation [444; 445]. The calcium remains 
important for the dimerization but it can be substituted by a residue of Lys250. 
The coordination of Lys250 in the binding site of repeat II is mediated by the 
backbone carbonyl oxygen atoms of Lys128, Gly129 and Gly131 residues in 
the same loop in the absence of calcium in the full length ANXA1 structure. 
On the other hand, calcium ion in the type II-binding site of repeat II arranges 
itself in the middle f the backbone carbonyl oxygen atoms of Met127, Gly129 
and Gly131 and Asp171 (two water molecules complete the coordination 
sphere but are not shown in here). However, it is not known whether the 
crystallographic dimer represents a physiological dimer [206]. 
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As the results of this PhD project indicate that both intracellular and 
extracellular ANXA1 is involved in promoting progression and metastatization 
of PC cells, the protein may represent an attractive target for pharmacological 
modulation. For this reason, we promoted the construction of peptides that 
can inhibit the protein effects. This section focuses on the computational 
design of this molecules and other biochemical experiments have been 
executed to test the peptide sequence planned and synthesized.  
 
 
A.2 Methods and results 
The approach we used is based on the aspect for which the structure 
of full length ANXA1 in the absence of calcium represents the inactive form of 
the protein with its N-terminal domain buried inside to the protein core. Upon 
calcium-mediated membrane binding, the N-terminal domain is ejected from 
the hydrophobic pocket formed by repeat III and ends up solvent-accessible 
on the concave side of the molecule. In this proposed activated conformation, 
the two α-helices of the N-terminal domain would be free to move around via 
the flexible linker formed by residues 27-41. After this calcium-triggered 
switch in conformation the previously buried N-terminal domain would be free 
to interact with new partners. These could include that S100A11 protein or a 
second ANXA1 molecule can bind the N-terminal domain of ANXA1. 
However, it is tempting to speculate that each Ca2+/membrane-activated 
ANXA1 molecule could now bind to a second membrane via its exposed N-
terminal domain providing a mechanism for membrane aggregation; this 
model is still not well defined [208; 209; 446].  
The modeling study was organized in three section. Firstly, new 
sequences capable to bind specifically the N-terminal portion of ANXA1 have 
been prepared for an in silico screening. A combinatorial approach, swapping 
4 residues (namely 230, 253, 255, and 261) with a small subset of amino 
acids (polar, apolar, and charged) has been used. Successively, we have 
checked the stability of the designed peptides and their ability to bind ANXA1. 
The stability and the conformation of the peptides have been tested by means 
of molecular dynamics (MD). Finally, the free energy of binding of the dimer 
ANXA1-inhibitor was calculated by steered molecular dynamics (SMD) 
method. 
 
A.2.1 Design of new sequences 
The design of potential inhibitor of ANXA1 started from the wild type 
sequence of annexin (uniprot P04083). The three helix surrounding the N-
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term of ANXA1 with a length of 44 residues, have been considered as a 
starting point for punctual mutations. To reduce the number of peptides 
generated by combinatorial approach, we focused mutations on the residues 
230, 253, 255, and 261, only. These amino acids have been replaced with Ala 
(hydrophobic), Ser (polar), Lys (positive), Asp (negative), and Cys, for a total 
of 625 peptides. 
Most of these peptides were suspected to have no secondary 
structure and a preliminary analysis with the use of HMM analysis 
(http://toolkit.tuebingen.mpg.de/hhpred) was conducted. The peptides with a 
plausible secondary structure have been further controlled by MD. 
 
A.2.2 Structure check 
Several peptides have been selected for structure check. It was 
important to determine if a peptide can spontaneously acquire a clear and 
stable secondary structure, and/or a secondary structure can be observed 
upon binding with the N-terminal portion of ANXA1. 
The propensity to acquire spontaneously a secondary structure was 
checked via ab initio folding of the peptides (implicit water MD). The stability 
of peptides alone and of the complexes were controlled by all atom molecular 
dynamics, starting from the folding structure obtained by homology. The 
RMSD of the peptide is followed for 50 ns and calculated respect the initial 
structure.  
Molecular dynamics simulations were performed using the script 
protein_folding_by_MD.js accessible in Abalone software 
(http://www.biomolecular-modeling.com/Abalone/), setting AMBER94 force 
field, temperature to 350 K and implicit water model (Fig. A.3). After force field 
assigning, we performed structure optimization to avoid overlapping. The 
simulation time of 50 ns was sufficient to reach the native protein 
conformation. Also to reduce the computational time and cost we used a grid 
(GRIMD) to distribute all jobs [447]. Energy minimization was carried out with 
combined steepest descent and simulated annealing by fixing the backbone 
atoms of the aligned residues to avoid potential damage to the initial model. 
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Figure A.3: comparison between 3D-structure of ANXA1 wt and ab initio folded 
inhibitor. On the left is reported the portion of 44 residues of ANXA1 surrounding the 
N-term portion (in red). On the right is shown a designed inhibitor folded by MD. MD 
technique was able to fold peptides mimicking the 3D-structure of the ANXA1 wild 
type. 
 
A.2.3 Binding energy calculation 
The free energy of binding was then calculated to make an esteem of 
the affinity of these peptides. The steered molecular dynamics (SMD) 
technique was chosen.  
Each system consisted of a potential inhibitor and the core domain of 
the ANXA1 portion. 
We collected the trajectory traced when the N-terminal helix of the 
ANXA1 is pulled from the inhibitor to the outside. The SMD was carried out 
using the software YASARA Structure 15.6.21 [448]. 
The starting structure for the simulations of the ANXA1 was extracted 
from the X-ray structures from the PDB database (PDB code 1HM6). Other 
molecules have been removed. A cubic periodic simulation cell of 512000 Å3 
was built around the entire complex.  
The charges were assigned at physiological conditions (pH 7.4). The 
simulation box was filled with water choosing a density of 0.997 g/mL.  
The simulation cell was neutralized with NaCl with a final 
concentration of 0.9%. We minimized the energy of the system using first a 
steepest descent minimization followed by a simulated annealing 
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minimization. The pulling acceleration of the ligand was 3 Å/ps2. The 
simulation was stopped when the distance between the centers of mass of 
receptor and ligand was > 30 Å. 
Several snapshots were selected from the SMD simulation at regular 
time intervals (each 500 ps). All simulations were performed with the software 
YASARA Structure 15.6.21. A simulation cell was centered and dimensions of 
the box were adapted for each structure to cover the entirety of the system. 
We used AMBER03 as force field with long-ranged PME potential and a cutoff 
of 8.0 Å, under periodic boundary conditions. We calculates the binding 
energy between the N-term of ANXA1 and the potential inhibitor according to 




Figure A.4: binding energy evolution evaluated by SMD. The more positive values of 
the binding energy correspond to better interaction. We used a scrambled peptide as 
negative control, while the portion of ANXA1 of 44 residues surrounding the N-term 
portion has been taken as positive control. The scrambled peptide was capable to 
interact to the N-terminal portion of ANXA1 through unspecific and transient weak 
interactions. All but the scrambled peptide showed a high and specific interaction 
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